《伤寒论》泄热三方对AS模型大鼠炎症机制影响的比较研究
|
摘要
动脉粥样硬化类疾病的发病率在我国乃至全世界呈现逐年上升趋势,从最初的脂质浸润学说到当今的炎症学说,国内外医学工作者从未间断过对其发病机制的研究。既往及现有的研究结果一致认为,动脉粥样硬化(AS)的形成与发展与脂质沉积、动脉内皮损伤、血管平滑肌细胞迁移及增殖、血小板的聚集、炎性因子的异常分泌等因素密切相关。随着研究的深入,炎症及免疫机制在AS的形成、发展过程中起着越来越重要的作用,控制或阻断炎性机制通路及抑制炎症因子的表达,正成为防治AS新的研究方向。
近些年来祖国医学防治AS类疾病的疗效已得到医学界的认可,许多经方被应用于AS类疾病的临床治疗,其治疗AS的基础及临床研究均取得了一定的进展。但当今大多数学者偏重于从血瘀、痰浊等方面进行论治,而从热毒辨治的报道相对较少。中医清热解毒类药物有类似于西药“抗炎”的作用,且其治疗AS的作用机制亦有相关基础性研究报道。针对当前中西医学者对AS病理实质所提出的热毒致病和炎症学说,立足于炎症机制的角度,在应用活血及化痰药物的同时使用清热解毒类药物,或在西医常规降脂的基础上联合清热解毒类药物,可为中西医结合防治AS类疾病提供一个新的切入点。
目的
桃核承气汤、小陷胸汤、大黄黄连泻心汤是《伤寒论》中总体上具有清泄邪热作用三首经方,然又根据其组方不同,三方在泄热的同时分别侧重于活血、化痰、清热三个方面。既往的实验及临床研究报道发现,三方均有防治AS类疾病的作用。本实验旨在探讨《伤寒论》三方对动脉粥样硬化大鼠核转录因子-κB(NF-κB)及其所介导的炎症因子之间的影响作用,以探明泄热类经方对AS类疾病炎症机制的作用机理。同时,也从侧重活血、化痰、清热三个不同方面观察《伤寒论》三方对炎症机制作用的不同,为临床防治AS类疾病提供理论依据,具有一定的理论及临床意义。
方法
1.理论研究：通过文献梳理祖国医学对AS病名、病机的认识；探讨中医传统病因学、中医脏腑病变与AS的关系。梳理《伤寒论》三方历代临床研究及现代抗AS的实验研究情况。
2.实验研究：通过建立大鼠AS模型,观察《伤寒论》三方对AS炎症机制的影响作用,比较三方作用的差异。具体方法如下：
①通过病理切片观察AS大鼠主动脉形态学的改变；观测主动脉内膜、中膜厚度的改变情况；
②运用ELISA法检测AS大鼠血清中ox-LDL、VCAM-1、IL-6浓度；
③运用免疫比浊法测定AS大鼠血清CRP含量；
④运用免疫组化法测定AS大鼠主动脉中CD40表达水平；
⑤运用Western blot法测定AS大鼠主动脉中NF-κB表达情况。
结果
1.通过理论研究及整理发现：祖国医学认为动脉粥样硬化的形成与心、肝、脾、肾、肺密切相关,总体上为本虚标实之证；瘀血、痰浊、气滞、热毒、湿热是其形成的主要病理因素；《伤寒论》三方从临床及实验研究来看均有防治AS的作用。
2.通过实验研究发现：
①光镜下观察《伤寒论》三方AS大鼠主动脉切片发现：三方均能保护动脉内皮,明显抑制平滑肌细胞的增殖和迁移,抑制炎性细胞的分泌和浸润,阻止动脉粥样硬化斑块的形成。通过对中药组大鼠主动脉切片内膜厚度(IT)、中膜厚度(MT)厚度统计分析后发现,三方IT、MT的数值与病理模型组相比均有统计学差异(P<0.05)。组间比较发现,桃核承气汤组IT、MT数值与其它两组有统计学差异(P<0.05)。
②通过对《伤寒论》三方AS大鼠血清ox-LDL、VCAM-1、IL-6、CRP的检测结果分析发现：中药组大鼠ox-LDL、VCAM-1、IL-6、CRP的水平与病理模型组相比有统计学差异(P<0.05)。组间比较发现：小陷胸汤组ox-LDL的水平与其它两组有统计学差异(P<0.05)；桃核承气汤组VCAM-1的水平与其它两组有统计学差异(P＜0.05)；大黄黄连泻心汤组IL-6的水平与其它两组有统计学差异(P<0.05)；桃核承气汤组、大黄黄泻心汤组CRP水平与小陷胸汤组相比有统计学差异(P<0.05),桃核承气汤组、大黄黄泻心汤组相比,差异无统计学意义(P>0.05)。
③通过对《伤寒论》三方AS大鼠主动脉CD40的阳性光密度值统计分析后发现：中药组大鼠CD40的水平与病理模型组相比有统计学差异(P<0.05)。组间比较发现：桃核承气汤组、大黄黄泻心汤组CD40水平与小陷胸汤组相比有统计学差异(P<0.05)；桃核承气汤组、大黄黄泻心汤组相比,差异无统计学意义(P>0.05)。
④通过对《伤寒论》三方AS大鼠主动脉NF-κB的Western blot检测结果分析发现：中药组大鼠NF-κB的水平与病理模型组相比有统计学差异(P<0.05)。经组间比较发现：桃核承气汤组NF-κB水平与其它两方有统计学差异(P<0.05)。
⑤用直线相关分析中药组NF-κB与ox-LDL、VCAM-1、IL-6、CRP、CD40之间的直线相关系数(r),结果为：桃核承气汤组：0.872、0.854、0.861、0.897、0.811(P<0.05)；小陷胸汤组：0.892、0.754、0.844、0.654、0.731(P<0.05)；大黄黄连泻心汤组：0.677、0.737、0.878、0.891、0.802(P<0.05)。
结论
1.《伤寒论》三方均能有效地抑制动脉粥样硬化斑块的形成。其中,桃核承气汤对AS大鼠主动脉形态学改变的保护作用相对最好。
2.《伤寒论》三方不但对NF-κB、ox-LDL、VCAM-1、IL-6、CRP、CD40等单个指标有抑制作用,更能从总体上抑制NF-κB所介导的IL-6等炎症因子所诱发的炎症及免疫反应,从炎症机制的角度在总体上对动脉粥样硬化进行调节和治疗,从而起到防治作用。
3.从总体上来看,《伤寒论》三方中桃核承气汤组各项指标改善明显,说明其总体疗效最佳。提示临床上在治疗AS类疾病时,在传统的活血及化痰治法的基础上适当的辅以清热解毒、顾护脾胃类药物,有助于增强疗效。
The incidence atherosclerotic diseases had showed a rising trend in our country and around the world.From the initial lipid infiltration theory to today's inflammation theory, domestic and foreign medical workers never stopped its pathogenesis. The past and the present study agreed that the formation and development of atherosclerosis (AS) were closely related to lipid deposition, arterial endothelial injury, vascular smooth muscle cell migration and proliferation, platelet aggregation, abnormal secretion of factors.With further research, Inflammatory and immune mechanisms in the formation and development process of AS plays an increasingly important role, controlling or blocking the inflammatory mechanisms pathway and inhibiting the expression of inflammatory factors are becoming the new research directions that treating AS.
In recent years, the efficacy that TCM preventing and treating the atherosclerotic diseases has been recognized by the medical profession, many classic recipe has been used in clinical treatment of atherosclerotic diseases, the basic and clinical research of treating AS had achieved some progress. But most nowaday scholars are emphasis on treatment from the blood stasis and phlegm, the reports that treating AS from the toxic heat are relatively fewer.The traditional Chinese medicine (TCM) of clearing and detoxifying have the effect of "anti-inflammatory" which is similar to western medicine, and the mechanisms of treating AS also have basic research reports.To the toxic heat and inflammation hypothesis for pathological mechanisms that the current traditional Chinese and western medicine scholars had suggested, based on the angle of the inflammatory mechanisms, while using the blood-activating drug and apophlegmatisant we use the heat-clearing and detoxicating drug, or jointing the heat-clearing and detoxicating drug on the basis of western medicine conventional lipid-lowering, which providing a new entry point for combining traditional Chinese and western medicine to treating atherosclerotic diseases.
Object
TaoHeChengQi decoction, XiaoXianXiong decoction and DaHuangHuangLianXieXin decoction are the three classical decoctions which have the effect of reducing heat as a whole.However, according to difference of their formation, the three decoctions focus on the three aspect of activating blood, phlegm and reducing heat. Previous experimental and clinical study reports indicated that the three decoctions had the effect of treating atherosclerotic diseases. The study is designed to research the effect between nuclear factor-kappaB (NF-κB) and NF-κB-mediated inflammatory factor, which ascertain the mechanism that reducing-heat classical decoctions treating atherosclerotic diseases.At the same time, from the aspect of activating blood, phlegm and reducing heat observing the difference to inflammatory mechanism and providing a theoretical basis for the prevention and treatment of atherosclerotic diseases, which have some theoretical and clinical significance.
Method
1.Theoretical Study:Organizing the understanding of Chinese medicine to the disease name and pathogenesis of AS through literature searching; Discussing the relationship among TCM etiology, TCM organs lesions and AS.Organizing the clinical studies in different dynasties and experimental studies that the three decoctions in ShangHanLun treating AS.
2.Experimental study:Through building the rat AS model, observing the influence the three decoctions in ShangHanLun inflammatory mechanism of AS, Comparing the difference of Mechanism of action of the three decoctions.The specific method is as follows:
①Observing the changing of AS rats in aortic morphology, observing the changing of aortic IT and MT;
②Testing the concentration of ox-LDL, VCAM-1, IL-6in AS rat serum by ELISA;
③Testing the concentration of CRP in AS rat serum by latex immune turbidimetry;
④Testing the level of CD40expression in AS rat aorta by immunohistochemical method;
⑤Testing the level of NF-κB expression in AS rat aorta by western blot.
Result
1.Through theoretical study we have found that:TCM thinks that the formation of atherosclerosis is closely related to heart, liver, spleen, kidney, lung, which attributed to primary deficiency and secondary excess; and the blood stasis, phlegm, qi stagnation, toxic heat, hot and humid are the main pathological factors of formation; the three decoctions in ShangHanLun have the effect of prevention and treatment to AS in the clinical and experimental studies.
2.Through experimental study we have found that:
①By observing the slices of rat aorta we have found that:the three decoctions all can protecting the arterial endothelial, significantly inhibiting the increase and migration of smooth muscle cells, inhibiting the secretion and infiltration of inflammatory cells, preventing the formation of atherosclerotic plaque.By statistical analysissing to the intima thickness (IT) and the middle thickness (MT) of the chinese medicine groups rat aortic slices we have found that:compared to the pathological model group, the difference of quantitative value of IT and MT are statistically significant (P<0.05).Compared with other medicine groups, the difference of quantitative value of IT and MT of TaoHeChengQi decoction are statistically significant (P<0.05)
②By analysing the result of AS serum ox-LDL, VCAM-1, IL-6and CRP of the three decoctions in ShangHanLun we have found that:Chinese medicine groups comparing with pathological model group, the difference are statistically significant (P<0.05).Compared with other medicine groups, the difference of the level of ox-LDL of XiaoXianXiong decoction is statistically significant(P<0.05);the difference of the level of VCAM-1of TaoHeChengQi decoction is statistically significant (P<0.05); the difference of the level of IL-6of DaHuangHuangLianXieXin decoction is statistically significant (P<0.05).TaoHeChengQi decoction and DaHuangHuangLianXieXin groups comparing with XiaoXianXiong decoction group, the difference of the level of CRP are statistically significant (P<0.05); TaoHeChengQi decoction group comparing with DaHuangHuangLianXieXin decoction group, the difference is no statistical (P>0.05)
③By analysing the result of AS rats aortic CD40-positive optical density values we have found that:Chinese medicine groups comparing with pathological model group, the difference are statistically significant (P<0.05).Compared with XiaoXianXiong decoction group, the difference of the level of CD40of TaoHeChengQi and DaHuangHuangLianXieXin decoction are statistically significant (P<0.05); TaoHeChengQi decoction group comparing with DaHuangHuangLianXieXin decoction group, the difference is no statistical (P>0.05)
④By analysing the result of western blot of AS rats aortic NF-κB we have found that:Chinese medicine groups comparing with pathological model group, the difference are statistically significant (P<0.05).Compared with other medicine groups, the difference of the level of NF-κB of TaoHeChengQi decoction are statistically significant (P<0.05)
⑤By linear correlation analysing the linear correlation coefficient (r) between NF-κB and ox-LDL、VCAM-1、IL-6、CRP、CD40of Chinese medicine groups, the result are:TaoHeChengQi decoction group:0.872、0.854、0.861、0.897、0.811(P<0.05); XiaoXianXiong decoction group:0.892、0.754、0.844、0.654、0.731(P<0.05); DaHuangHuangLianXieXin decoction group:0.677、0.737、0.878、0.891、0.802(P<0.05)
Conclusion
1.The three decoctions in ShangHanLun all can effectively inhibitting the formation of atherosclerosis plaque.Among them, TaoHeChengQi decoction has the relatively best protective effect to the AS rats aortic morphological changes.
2.The three decoctions in ShangHanLun not only have the inhibiting effect to NF-κB、ox-LDL、VCAM-1、IL-6、CRP、CD40, but also can general inhibiting the inflammation and immune response which induced by NF-κB-mediated IL-6and other inflammatory factors. From the perspective of the inflammatory mechanisms generally regulating and treating atherosclerosis.
3.From generally speaking, TaoHeChengQi decoction group improved the various indexs significantly, which proving its treating effect is the best in three decoctions in ShangHanLun.When we treating atherosclerotic diseases, on the basis of invigorating blood and reducing phlegm therapy appropriate using chinese medince of clearing heat and detoxicating, benefitting Spleen And Stomach, which can improving effect.
近些年来祖国医学防治AS类疾病的疗效已得到医学界的认可,许多经方被应用于AS类疾病的临床治疗,其治疗AS的基础及临床研究均取得了一定的进展。但当今大多数学者偏重于从血瘀、痰浊等方面进行论治,而从热毒辨治的报道相对较少。中医清热解毒类药物有类似于西药“抗炎”的作用,且其治疗AS的作用机制亦有相关基础性研究报道。针对当前中西医学者对AS病理实质所提出的热毒致病和炎症学说,立足于炎症机制的角度,在应用活血及化痰药物的同时使用清热解毒类药物,或在西医常规降脂的基础上联合清热解毒类药物,可为中西医结合防治AS类疾病提供一个新的切入点。
目的
桃核承气汤、小陷胸汤、大黄黄连泻心汤是《伤寒论》中总体上具有清泄邪热作用三首经方,然又根据其组方不同,三方在泄热的同时分别侧重于活血、化痰、清热三个方面。既往的实验及临床研究报道发现,三方均有防治AS类疾病的作用。本实验旨在探讨《伤寒论》三方对动脉粥样硬化大鼠核转录因子-κB(NF-κB)及其所介导的炎症因子之间的影响作用,以探明泄热类经方对AS类疾病炎症机制的作用机理。同时,也从侧重活血、化痰、清热三个不同方面观察《伤寒论》三方对炎症机制作用的不同,为临床防治AS类疾病提供理论依据,具有一定的理论及临床意义。
方法
1.理论研究：通过文献梳理祖国医学对AS病名、病机的认识；探讨中医传统病因学、中医脏腑病变与AS的关系。梳理《伤寒论》三方历代临床研究及现代抗AS的实验研究情况。
2.实验研究：通过建立大鼠AS模型,观察《伤寒论》三方对AS炎症机制的影响作用,比较三方作用的差异。具体方法如下：
①通过病理切片观察AS大鼠主动脉形态学的改变；观测主动脉内膜、中膜厚度的改变情况；
②运用ELISA法检测AS大鼠血清中ox-LDL、VCAM-1、IL-6浓度；
③运用免疫比浊法测定AS大鼠血清CRP含量；
④运用免疫组化法测定AS大鼠主动脉中CD40表达水平；
⑤运用Western blot法测定AS大鼠主动脉中NF-κB表达情况。
结果
1.通过理论研究及整理发现：祖国医学认为动脉粥样硬化的形成与心、肝、脾、肾、肺密切相关,总体上为本虚标实之证；瘀血、痰浊、气滞、热毒、湿热是其形成的主要病理因素；《伤寒论》三方从临床及实验研究来看均有防治AS的作用。
2.通过实验研究发现：
①光镜下观察《伤寒论》三方AS大鼠主动脉切片发现：三方均能保护动脉内皮,明显抑制平滑肌细胞的增殖和迁移,抑制炎性细胞的分泌和浸润,阻止动脉粥样硬化斑块的形成。通过对中药组大鼠主动脉切片内膜厚度(IT)、中膜厚度(MT)厚度统计分析后发现,三方IT、MT的数值与病理模型组相比均有统计学差异(P<0.05)。组间比较发现,桃核承气汤组IT、MT数值与其它两组有统计学差异(P<0.05)。
②通过对《伤寒论》三方AS大鼠血清ox-LDL、VCAM-1、IL-6、CRP的检测结果分析发现：中药组大鼠ox-LDL、VCAM-1、IL-6、CRP的水平与病理模型组相比有统计学差异(P<0.05)。组间比较发现：小陷胸汤组ox-LDL的水平与其它两组有统计学差异(P<0.05)；桃核承气汤组VCAM-1的水平与其它两组有统计学差异(P＜0.05)；大黄黄连泻心汤组IL-6的水平与其它两组有统计学差异(P<0.05)；桃核承气汤组、大黄黄泻心汤组CRP水平与小陷胸汤组相比有统计学差异(P<0.05),桃核承气汤组、大黄黄泻心汤组相比,差异无统计学意义(P>0.05)。
③通过对《伤寒论》三方AS大鼠主动脉CD40的阳性光密度值统计分析后发现：中药组大鼠CD40的水平与病理模型组相比有统计学差异(P<0.05)。组间比较发现：桃核承气汤组、大黄黄泻心汤组CD40水平与小陷胸汤组相比有统计学差异(P<0.05)；桃核承气汤组、大黄黄泻心汤组相比,差异无统计学意义(P>0.05)。
④通过对《伤寒论》三方AS大鼠主动脉NF-κB的Western blot检测结果分析发现：中药组大鼠NF-κB的水平与病理模型组相比有统计学差异(P<0.05)。经组间比较发现：桃核承气汤组NF-κB水平与其它两方有统计学差异(P<0.05)。
⑤用直线相关分析中药组NF-κB与ox-LDL、VCAM-1、IL-6、CRP、CD40之间的直线相关系数(r),结果为：桃核承气汤组：0.872、0.854、0.861、0.897、0.811(P<0.05)；小陷胸汤组：0.892、0.754、0.844、0.654、0.731(P<0.05)；大黄黄连泻心汤组：0.677、0.737、0.878、0.891、0.802(P<0.05)。
结论
1.《伤寒论》三方均能有效地抑制动脉粥样硬化斑块的形成。其中,桃核承气汤对AS大鼠主动脉形态学改变的保护作用相对最好。
2.《伤寒论》三方不但对NF-κB、ox-LDL、VCAM-1、IL-6、CRP、CD40等单个指标有抑制作用,更能从总体上抑制NF-κB所介导的IL-6等炎症因子所诱发的炎症及免疫反应,从炎症机制的角度在总体上对动脉粥样硬化进行调节和治疗,从而起到防治作用。
3.从总体上来看,《伤寒论》三方中桃核承气汤组各项指标改善明显,说明其总体疗效最佳。提示临床上在治疗AS类疾病时,在传统的活血及化痰治法的基础上适当的辅以清热解毒、顾护脾胃类药物,有助于增强疗效。
The incidence atherosclerotic diseases had showed a rising trend in our country and around the world.From the initial lipid infiltration theory to today's inflammation theory, domestic and foreign medical workers never stopped its pathogenesis. The past and the present study agreed that the formation and development of atherosclerosis (AS) were closely related to lipid deposition, arterial endothelial injury, vascular smooth muscle cell migration and proliferation, platelet aggregation, abnormal secretion of factors.With further research, Inflammatory and immune mechanisms in the formation and development process of AS plays an increasingly important role, controlling or blocking the inflammatory mechanisms pathway and inhibiting the expression of inflammatory factors are becoming the new research directions that treating AS.
In recent years, the efficacy that TCM preventing and treating the atherosclerotic diseases has been recognized by the medical profession, many classic recipe has been used in clinical treatment of atherosclerotic diseases, the basic and clinical research of treating AS had achieved some progress. But most nowaday scholars are emphasis on treatment from the blood stasis and phlegm, the reports that treating AS from the toxic heat are relatively fewer.The traditional Chinese medicine (TCM) of clearing and detoxifying have the effect of "anti-inflammatory" which is similar to western medicine, and the mechanisms of treating AS also have basic research reports.To the toxic heat and inflammation hypothesis for pathological mechanisms that the current traditional Chinese and western medicine scholars had suggested, based on the angle of the inflammatory mechanisms, while using the blood-activating drug and apophlegmatisant we use the heat-clearing and detoxicating drug, or jointing the heat-clearing and detoxicating drug on the basis of western medicine conventional lipid-lowering, which providing a new entry point for combining traditional Chinese and western medicine to treating atherosclerotic diseases.
Object
TaoHeChengQi decoction, XiaoXianXiong decoction and DaHuangHuangLianXieXin decoction are the three classical decoctions which have the effect of reducing heat as a whole.However, according to difference of their formation, the three decoctions focus on the three aspect of activating blood, phlegm and reducing heat. Previous experimental and clinical study reports indicated that the three decoctions had the effect of treating atherosclerotic diseases. The study is designed to research the effect between nuclear factor-kappaB (NF-κB) and NF-κB-mediated inflammatory factor, which ascertain the mechanism that reducing-heat classical decoctions treating atherosclerotic diseases.At the same time, from the aspect of activating blood, phlegm and reducing heat observing the difference to inflammatory mechanism and providing a theoretical basis for the prevention and treatment of atherosclerotic diseases, which have some theoretical and clinical significance.
Method
1.Theoretical Study:Organizing the understanding of Chinese medicine to the disease name and pathogenesis of AS through literature searching; Discussing the relationship among TCM etiology, TCM organs lesions and AS.Organizing the clinical studies in different dynasties and experimental studies that the three decoctions in ShangHanLun treating AS.
2.Experimental study:Through building the rat AS model, observing the influence the three decoctions in ShangHanLun inflammatory mechanism of AS, Comparing the difference of Mechanism of action of the three decoctions.The specific method is as follows:
①Observing the changing of AS rats in aortic morphology, observing the changing of aortic IT and MT;
②Testing the concentration of ox-LDL, VCAM-1, IL-6in AS rat serum by ELISA;
③Testing the concentration of CRP in AS rat serum by latex immune turbidimetry;
④Testing the level of CD40expression in AS rat aorta by immunohistochemical method;
⑤Testing the level of NF-κB expression in AS rat aorta by western blot.
Result
1.Through theoretical study we have found that:TCM thinks that the formation of atherosclerosis is closely related to heart, liver, spleen, kidney, lung, which attributed to primary deficiency and secondary excess; and the blood stasis, phlegm, qi stagnation, toxic heat, hot and humid are the main pathological factors of formation; the three decoctions in ShangHanLun have the effect of prevention and treatment to AS in the clinical and experimental studies.
2.Through experimental study we have found that:
①By observing the slices of rat aorta we have found that:the three decoctions all can protecting the arterial endothelial, significantly inhibiting the increase and migration of smooth muscle cells, inhibiting the secretion and infiltration of inflammatory cells, preventing the formation of atherosclerotic plaque.By statistical analysissing to the intima thickness (IT) and the middle thickness (MT) of the chinese medicine groups rat aortic slices we have found that:compared to the pathological model group, the difference of quantitative value of IT and MT are statistically significant (P<0.05).Compared with other medicine groups, the difference of quantitative value of IT and MT of TaoHeChengQi decoction are statistically significant (P<0.05)
②By analysing the result of AS serum ox-LDL, VCAM-1, IL-6and CRP of the three decoctions in ShangHanLun we have found that:Chinese medicine groups comparing with pathological model group, the difference are statistically significant (P<0.05).Compared with other medicine groups, the difference of the level of ox-LDL of XiaoXianXiong decoction is statistically significant(P<0.05);the difference of the level of VCAM-1of TaoHeChengQi decoction is statistically significant (P<0.05); the difference of the level of IL-6of DaHuangHuangLianXieXin decoction is statistically significant (P<0.05).TaoHeChengQi decoction and DaHuangHuangLianXieXin groups comparing with XiaoXianXiong decoction group, the difference of the level of CRP are statistically significant (P<0.05); TaoHeChengQi decoction group comparing with DaHuangHuangLianXieXin decoction group, the difference is no statistical (P>0.05)
③By analysing the result of AS rats aortic CD40-positive optical density values we have found that:Chinese medicine groups comparing with pathological model group, the difference are statistically significant (P<0.05).Compared with XiaoXianXiong decoction group, the difference of the level of CD40of TaoHeChengQi and DaHuangHuangLianXieXin decoction are statistically significant (P<0.05); TaoHeChengQi decoction group comparing with DaHuangHuangLianXieXin decoction group, the difference is no statistical (P>0.05)
④By analysing the result of western blot of AS rats aortic NF-κB we have found that:Chinese medicine groups comparing with pathological model group, the difference are statistically significant (P<0.05).Compared with other medicine groups, the difference of the level of NF-κB of TaoHeChengQi decoction are statistically significant (P<0.05)
⑤By linear correlation analysing the linear correlation coefficient (r) between NF-κB and ox-LDL、VCAM-1、IL-6、CRP、CD40of Chinese medicine groups, the result are:TaoHeChengQi decoction group:0.872、0.854、0.861、0.897、0.811(P<0.05); XiaoXianXiong decoction group:0.892、0.754、0.844、0.654、0.731(P<0.05); DaHuangHuangLianXieXin decoction group:0.677、0.737、0.878、0.891、0.802(P<0.05)
Conclusion
1.The three decoctions in ShangHanLun all can effectively inhibitting the formation of atherosclerosis plaque.Among them, TaoHeChengQi decoction has the relatively best protective effect to the AS rats aortic morphological changes.
2.The three decoctions in ShangHanLun not only have the inhibiting effect to NF-κB、ox-LDL、VCAM-1、IL-6、CRP、CD40, but also can general inhibiting the inflammation and immune response which induced by NF-κB-mediated IL-6and other inflammatory factors. From the perspective of the inflammatory mechanisms generally regulating and treating atherosclerosis.
3.From generally speaking, TaoHeChengQi decoction group improved the various indexs significantly, which proving its treating effect is the best in three decoctions in ShangHanLun.When we treating atherosclerotic diseases, on the basis of invigorating blood and reducing phlegm therapy appropriate using chinese medince of clearing heat and detoxicating, benefitting Spleen And Stomach, which can improving effect.
引文
[1]孟国凡.动脉粥样硬化的中医病因病机初探[J].云南中医中药杂志,2004,25(2)：55-56.
[2]李国强,胡业彬.毒邪致动脉粥样硬化的病因病机探讨[J].河南中医,2010,30(12)：1155-1156.
[3]吴天敏,杜建.中医药抗动脉粥样硬化的研究概况[J].福建中医学院学报,2006,16(3)：67-69.
[4]张艳,杨关林,于睿,等.动脉粥样硬化中医虚瘀痰毒病因病机实质研究探讨[J].时珍国医国药,2007,18(6)：1513-1514.
[5]董美玲,徐云生.从脾胃论治冠心病[J].贵阳中医学院学报,2009,31(6)：7-9.
[6]程小曲.痰浊型冠心病与血脂、脂蛋白、载脂蛋白的关系及痰浊形成机理的探讨[J].新中医.1994,26(3)：7-9.
[7]张京春,陈可冀.瘀毒病机与动脉粥样硬化易损斑块相关的理论思考[J].中国中西医结合杂志,2008,28(4)：366-368.
[8]徐浩,史大卓,殷惠军,等.“瘀毒致变”与急性心血管事件：假说的提出与临床意义[J].中国中西医结合杂志,2008,28(10)：934-938.
[9]马晓昌,尹太英,陈可冀,等.冠心病中医辨证分型与冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(9)：654-656.
[10]张勤,崔晓萍,贾晓东.活血化瘀中药治疗动脉粥样硬化的研究进展[J].中医学报,2009,24(5)：126-127.
[11]邵致格.现代人群的体质病理学特征：气虚血瘀[J].医学与哲学,2005,26(4)：74-75.
[12]林代华.气虚血瘀是冠心病的病机关键释义[J].中医药学刊,2003,21(4)：588-589.
[13]刘洪.气虚血瘀证与血管内皮细胞相关因子的研究进展[J].中国中医基础医学杂志,2005,11(7)：553-556.
[14]林培政,杨开清.动脉粥样硬化中医湿热病机再认识[J].新中医,2006,38(3)：5-6.
[15]林培政,杨开清.动脉粥样硬化性疾病与中医湿热证的关系[J].中药新药与临床药理,2006,17(2)：147-149.
[16]陈浩,胡业彬.冠心病某些危险因素与“瘀毒”病因关系探讨[J].安徽中医学院学报,2009,28(4)：3-5.
[17]蔡云海.从热毒观念论治冠心病[J].光明中医,2009,24(5)：798-799.
[18]吴伟,彭锐.冠心病热毒病机的探讨[J].新中医,2007,39(6)：3-4.
[19]丁书文,李晓,李运伦.热毒学说在心系疾病中的构建与应用[J].山东中医药大学学报,2004,28(6)：413-416.
[20]王少英.清热解毒药物在治疗冠心病中的运用[J].北京中医,2004,23(1)：14.
[21]李建军.炎症可能是连接高血压和动脉粥样硬化的桥梁[J].中国分子心脏病学杂志,2005,5(1)：385-388.
[22]Koea, Amrif, Pandey NR, et al.Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation:evidence from m-CSF-deficient mice[J].Am J Physiol Heart Circ Physiol,2007,293 (4): H1789-H1795.
[23]Watson T, Goon PK, Lip GY.Endothelial progentor cells, endothelia ldsyfunction, inflammation, and oxidative stress in hypertension[J].Antioxid Redos Signal,2008, 10 (6):1079-1088
[24]Maya E, Redecke B, Gruner S, et al.Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice[J].Arterioscler Thromb Vasc Biol,2003,23(5):789-794.
[25]Ibrahim AI, Obeid MT, Jouma MJ, et al.Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaues and in unaffected bypass grafts[J].J Clin Virol,2005,32(1):29.
[26]孙余华,襄卫东.炎症与动脉粥样硬化基础和临床研究的新进展[J].中国循环杂志,2003,18(3)：232-235.
[27]Smith CJ, Fisher TH.Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction[J].Atherosclerosis,2001,158(2):257-267.
[28]MuCully, KS.Vascular pathology of homocysteinemia:implications for the pathogenesis of arteriosclerosis[J].Am J Pathol,1969,56:111-128.
[29]R Clarke, L Daly, K Robinson, et al.Hyperhomocysteinemia:an independent risk factor for vascular disease[J].N.Engl.J.Med, Apr 1991,324:1149-1155.
[30]SC Guba, LM Fink, and V Fonseca.Hyperhomocysteinemia.An emerging and important risk factor for thromboembolic and cardiovascular disease[J].Am J Clin Pathol,1996,106 (6):709-722.
[31]Goldbourt U, Neufeld HN. Genetic aspects of arteriosclerosis[J]. Arteriosclerosis, 1988,6:357-377.
[32]张运.动脉粥样硬化研究的当前问题[J].中国医药科学,2012,2(1)：9-11.
[33]McPherson R, Pertsemlidis A, Kavaslar N, et al.A common allele on chromosome 9 associated with coronary heart disease[J].Science, Jun 8 2007,3 16(5830):1488-1491.
[34]Schunkert H, Gotz A, Braund P, et al.Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease[J].Circulation,2008,117(13):1675-1684.
[35]Skaln K, Gustafsson M, Rydberg EK, et al.Subendothelial retention of atherogenic lipoproteins in early atherosclerosis[J].Nature,2002,417:750-754.
[36]Gouni-Berthold I, Sachinidis A.possible non-classic intracellular and molecular mechanism of LDL cholesterol action contributing to the development and progression of atherosclerosis[J].Curr vasc pharmacol,2004,2(4):363-70.
[37]Sheen AJ, Kulbertus H.Chinese study of the month.REVERAL and PROVE-IT: confirmation of the concept"the lower, the better"for cholesterol therapy in patients with coronary heart disease[J].[article in French]Rev Med Liege,2004,59(3):167-73.
[38]Olkkonen VM, Lehto M.Oxysterols and oxysterol binding proteins:role in lipid metabolism and atherosclerosis.Ann Med,2004,36 (8):562-572.
[39]Libby P.Molecular bases of the acute coronary syndromes[J].Circulation,1995,91: 2844-2850.
[40]WILSON AM, RYAN MC, BOYLE AL-The novel role of C-reactive protein in cardiovascular disease:risk maker or pathogen[J].Int J Cardiol,2006,106(3):291-297.
[41]Pasceri V, Chang J, Willerson JT, et al.Modulation of c-reactive protein-mediated monocyte chemoattractant protein-1 induction in humman endothelial cells by anti-atherosclerosis drugs[J].Circulation,2001,103(21):2531-2534.
[42]Verma S, Li SH, Badiwala MV, et al.Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein[J].Circulation, 2002,105 (16):1890-1896.
[43]Verma S, Wang CH, Li SH, et al.A self-fulfilling prophecy:C-reactive protein attenuates nitric oxide production and inhibits angiogenesis[J].Circulation,2002,106 (8):913-919.
[44]Venugopal SK, Devaraj S, Yuhanna I, et al.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells[J].Circulation,2002,106(12):1439-1441.
[45]Zwaka TP, Hombach V, Torzewski J.C-reactive protein-mediated low density lipoprotein uptake by macrophages:implicatios for atherosclerosis[J].Circulation, 2001,103 (9):1194-1197.
[46]Yeh ET, Anderson HV, Pasceri V, et al.C-reactive protein:linking inflammation to cardiovascular complications[J].Circulation,2001,104(9):974-975.
[47]何玉辉,刘惠亮.粘附分子与动脉粥样硬化关系的研究进展[J].疑难病杂志,2006,5(2)： 155-157.
[48]Poston RN, Haskard DO, Coucher JR, et al.Expression of intercellular adhesionmolecule-linatheroscleroticplaques[J].Am J Pathol,1992,140:665-673.
[49]Printeseva OY, Peclo MM, Goron AM.Various cell type in human atherosclerotic lesions express ICAM-1:Further immunocytochemical and immunochemical studies employing monoclonal antibody10F3[J].Am J Pathol,1992,140:896-899.
[50]Wu YQ, Zhang RJ, Zhou CH, et al.Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice [J].Atherosclerosis,2009,203 (2): 360-370.
[51]Li JJ, Li YS, Hui RT, et al.Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin-10 in patients with unstable angina[J].Heart,2006,92 (4):529-530.
[52]Flavia S, Francesca M, Mariapaola M, et al.IL-6-deficient mice showimpaired inflammatory response in a model of myosin induced experimental myositis[J].Journal of Neuroimmunology,2006,176(1-2):9-15.
[53]Ishai L, Ronni G, David P, et al.Elevated levels of CRP in ovarian hyperstimulation syndrome:an unrecognised potential hazard[J].BJOG,2005,112(7):952-955.
[54]Pau E, Alonso-Muriel I, Gomez R, et al.Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome[J].Hum Reprod,2006,21 (6):1453-1460.
[55]Harrington JR.The role of MCP-1 in atherosclerosis[J].Stem Cells,2000,18(1):65-66.
[56]Deo R, Khera A, Mcguire DK, et al.Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and sub clinical atherosclerosis[J].J Am Coll Cardiol,2004,44(9):1812-1818.
[57]Taleb S, Herbin O, Ait-Oufella H, et al.Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protectsmice from atherosclerosis[J].A rterioscler Thromb Vasc Biol,2007,27(12):2691-2698.
[58]Valentina C, Daniel N, Barbara ND, et al.CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure [J]. Atherosclerosis, 2007,190 (1):156-166.
[59]Xia M, Ling WH, Zhu HL, et al.Anthocyanin attenuates CD40-mediated endothelial cell activation and apoptosis by inhibiting CD40-induced MAPK activation[J].Atherosclerosis,2009,202 (1):41-47.
[60]JawienJ, Gajda M, Mateuszuk, et al.Inhibition ofnuclear factor-kpaB attenuates artherosclerosis in apoE/LDLR-double knockoutmice [J].Physiol Pharmacol,2005,56 (3):483-489.
[61]Lwaleed BA, Cooper AJ, Voegeli D, et al.Tissue factor:a critical role in inflammation and cancer[J].Biol Res Nurs,2007,9(2):97-107.
[62]Chu AJ.Role of tissue factor in thrombosis.Coagulation inflammation-thrombosis circuit[J].Front Biosci,2006,11:256-271.
[63]Skaln K, GustafssonM, RydbergE K, et al.Subendothelial retention of atherogenic lipoproteins in early atherosclerosis[J].Nature,2002,417:750-754.
[64]Waters DD, LaRosa JC, Barter P, et al.Effects of high-dose atorvastatin on erebrovascular events in patients with stable cornaary disease in the TNT (Treating to New Targets) Study [J].J Am Coll Cardiol,2006,48:1793-1799.
[65]Pedersen TR, Faerqueman O, Kastelein JJ, et al.High-dose atorva statin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study a randomized controlled trial [J]. JAM A,2005,294:2437-2445.
[66]中华医学会心血管病学分会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-419.
[67]Amarenco P, Bogousslavsky J, Callahan A, et al.The stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators high-dose atorvastatin afterstroke or transient is chemic attack[J].N Eng J Med,2006,355:549-559.
[68]赵志刚.抗动脉粥样硬化药物分类及研究进展[J].Chin J Arterioscler,2005, 13 (S1):52-56.
[69]中华医学会心血管病学分会等。正确认识合理使用调脂药物[J].中华心血管杂志,2001,29(12)：705-706.
[70]王素香,王拥军,尹洪超,等.PAS综合疗法对兔动脉粥样硬化的干预[J].中国动脉硬化杂志,2007,15(7)：542-543.
[71]曹剑,朱冰坡.普罗布考对老年下肢动脉硬化症的抗氧化和抗炎症作用[J].中国动脉硬化杂志.2006,14：336-338.
[72]严鹏科,廖端芳,杨永宗.普罗布考对巨噬细胞分泌基质金属蛋白酶9的抑制作用[J].中国动脉硬化杂志.2003,11：199-202.
[73]陈康寅,黄体钢.钙拮抗药在抗高血压治疗中的应用[J].中国现代神经疾病杂志,2007,7(2)：175-179.
[74]Harda SM, Kinoshita M, Kamido H, et al Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms[J].J Biol Chem,1998,273(16):9681-9687.
[75]Nichol KL, Nordin J, Mullooly J, et al.Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly[J].N Engl J Med, 2003,348 (14):1322-1332.
[76]张子新,赵卫华,宋丽新,等.阿奇霉素对动脉粥样硬化家兔炎症反应的影响[J].中国动脉硬化杂志,2006,14(7)：601-603.
[77]贾孟辉,于晓宁,贺晓慧.桃核承气汤加味治疗高脂血症43例疗效观察[J].宁夏医学院学报,2008,30(2)：249-251.
[78]杨丁友,马路,段学忠.桃核承气胶囊治疗高半胱氨酸血症40例[J].中医杂志,2003,44(6)：445-446.
[79]崔昕.桃核承气汤对多发性脑梗塞患者的疗效[J].国外医学·中医中药分册,1996,18(2)： 24-25.
[80]黄俊臣,周纪平,李彦春.核桃承气汤对脑梗死急性期辅助治疗作用的观察[J]. 安徽中医临床杂志,2003,15(4)：280.
[81]黎裕朝.小陷胸汤治疗冠心病28例[J].国医论坛,1999,14(6)：9.
[82]李景君,王蕊,徐京育.加味小陷胸汤治疗不稳定型心绞痛临床观察[J].中医药学报,2010,38(2)：123-124.
[83]孔秀英.小陷胸汤加味治疗冠心病心绞痛78例[J].中国中医急症,2008,17(5)：685.
[84]左建国.加味小陷胸汤联合辛伐他汀治疗高脂血症疗效观察[J].广东医学,2010,31(14)：1878-1880.
[85]路辉,王妍岩,袁春英.小陷胸汤加减治疗室性早搏60例[J].武警医学,1998,9(8)：453-454.
[86]高鸿,李厚根.小陷胸汤加减治疗病理性短阵室速32例[J].实用中医内科杂志,1999,13(1)： 44.
[87]刘东方,倪约翰.小陷胸汤对痰热蕴结型心悸的临床观察[J].中医药信息,2010,27(6)：19-21.
[88]万远铁,高春华,查丽.泻心通腑法治疗中风病162例疗效观察[J].湖北中医杂志,1991,13(4)：8-9.
[89]秦增祥.大黄黄连泻心汤药理和应用[J].中成药,1995,17(12)：39.
[90]泉正夫[日].三黄泻心汤胶囊治验一例及其考察[J].汉方研究,1991,(4)：14.
[91]赵雷,朱亮,钱义明,等.泻心汤配合西医常规治疗急性冠脉综合征20例炎性指标变化的观察[J].中医药导报,2008,14(7)：15-17.
[92]唐阿方.泻心胶囊治疗火邪热结型冠心病心绞痛的临床研究[D].长沙：湖南中医学院,2005.
[93]谢华,马越鸣,等.桃核承气汤对动物血栓形成及血小板聚集的影响[J].中成药,2006,11(28)：1631-1634.
[94]何赛萍,徐晓东,等.桃核承气汤对热瘀大鼠模型血液流变学和凝血指标的影响[J].浙江中医学院学报,2003,6(27)：56-57.
[95]喻秀兰,梅国强,张德玲,等.小陷胸汤加味含药血清对人脐静脉内皮细胞分泌NO／ET-1的调节作用[J].微循环学杂志,2005,15(2)：41-42.
[96]喻秀兰,梅国强,张德玲,等.加味小陷胸汤对氧化低密度脂蛋白致血管内皮细胞增殖和凋亡的影响[J].湖北中医学院学报,2005(7)2：6-7.
[97]郭志清,刘奇龙.小陷胸汤加味方对兔心肌缺血再灌注损伤MDA、SOD和CK-MB的影响[J].中国中医急症,2009,18(12)：2020-2021.
[98]吴智春,吴凯,王浩,等.金匮泻心汤抗动脉粥样硬化的实验研究[J].中国老年学杂志,2003,23(7)：461-462.
[99]王健,孙秀梅,张兆旺.大黄黄连泻心汤研究[J].中国现代医药,2005,4(6)：16-17.
[100]黄兆胜主编.全国高等中医药院校教材·中药学[M].北京：人民卫生出版社,2002： 137.
[101]郭志伟,刘琳娜.大黄及其有效成分的药理研究概况[J].中国药房,2006,17(22)： 1742.
[102]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响[J].中国中西医结合杂志,2005,25(4)：345.
[103]邓杰,王明明,方国安,等·大黄对脑创伤患者血清细胞因子的早期影响[J].中国临床药学杂志,2006,15(1)：50.
[104]侯家玉.中药药理学[M].北京：中国中医药出版社,2002：506.
[105]黄河清,刘培庆,黑子清,等.家兔实验性动脉粥样硬化时主动脉鞘磷脂酶活性与神经酰胺含量变化及大黄素的影响[J].中国病理生理杂志,2004,20(12)：2223-2226.
[106]潘浩,刘学波,张红旗,等.大黄素对人血管平滑肌细胞增殖的影响[J].解剖学研究,2004,26(2)：121.
[107]花拉,白茹玉,刘永喜.蒙药大黄药理研究进展[J].内蒙古民族大学学报,2007,22(1)： 80.
[108]姚文兵,陈琼华·大黄的生化学研究XXXIV波叶大黄多糖的抗血栓和强心作用[J].生化药物杂志,1991,1：42.
[109]于晓东.崔金海应用大黄治疗急性中风病经验[J].河北中医,2006,28(1)：5.
[110]段浩,张宏考,刘继军,等.小檗碱对兔颈动脉损伤后白介素-6等的影响[J]. 医药论坛杂志,2006,27(10)：6-9.
[111]HONG Y, HUI SC, CHAN TY, et al.Effect of betherine on regression of pressure overload induced cardiac hypertrophy in rats[J].Am J Chinese Micine,2002,30 (4): 588-599.
[112]易屏,陆付耳,陈广,等.小檗碱抑制核因子NF-κ Bp65表达及转位改善游离脂肪酸诱导的3T3-L1细胞胰岛素抵抗的分子机制[J].中国中西医结合杂志,2007,12(12)：1099-1103.
[113]吴迪,范明松,李志雄.小檗碱对心血管药理作用的研究进展[J].中国医药指南,2012,10(1)： 61-62.
[114]Liu IX, Durham DG, Richards RM.Baicalin synergy with beta-lactam antibiotics against methicillin-resistantStaphylococcus aureus and other beta-lactam-resistant strains of Saureus[J].J Pharm Pharmacol,2000,52(3):361-366.
[115]侯家玉.中药药理学[M].北京：中国中医药出版社,2002：80
[116]李敏,杨瑞芳.黄芩药理学研究进展综述[J].临床和实验医学杂志,2009,8(1)：137-138.
[117]Park WH, Shin SS, Lee YC, et al. The inhibitory effects of Silso-San-Gami-on atherosclerosis in KHC rabbits [J]. Thrornb Res,2004,113(34):235.
[118]耿涛,谢梅林,彭少平.桃仁提取物抗大鼠心肌缺血作用的研究[J].苏州大学学报,2005,25(2)：238.
[119]王新胜,吴艳芳,马军营,等.半夏化学成分和药理作用研究[J].齐鲁药事,2008,27(2)： 101-103.
[120]韩太云,王桂照,孟繁超,等.中药半夏提取物杭心律失常作用的实验研究[J].哈尔滨医科大学学报.1985,19(3)：75-77.
[121]腾守志,王桂照,付世英,等.半夏浸液杭心律失常的实验研究[J].中华心血管病杂志,1983,11(2)：103.
[122]洪往球,沃行德,何一中,等.半夏降血脂作用研究仁[J].浙江中医学院学报,1995,19(2)：28-29.
[123]刘进杨,杨志明,谭友庄.掌叶半夏碱乙对实验性血栓形成的影响[J].北京医药 工业,1984,(2)：13.
[124]沈雅琴,张明发,朱自平,等.半夏的抗腹泻和抗炎作用[J].中药药理与临床,1998,14(2)：29-31.
[125]张弢,沈文芳,朱俊.瓜蒌对心血管系统的药理作用及临床应用[J].中国乡村医药杂志,2007,14(11)：52.
[126]凌红.瓜蒌、心得安对血小板体外集聚和TXA2合成的影响[J].湖北医学院学报,1988,9 (2)： 138.
[127]上海市化工“七·二一”工人大学有机系中草药组.栝楼研究III,栝楼有效成分的研究初报-有效部位分离、药理及临床观察[J].医药工业,1975,(1)：15.
[128]李自成,常青.瓜蒌注射液对兔血管平滑肌细胞增殖细胞核抗原表达的影响[J].中国病理生理杂志,2000,16(6)：516-518.
[129]滕勇荣,王连侠,张永清.瓜蒌药理研究进展[J].齐鲁药事,2010,29(7)：417-419.
[130]志气保子.动脉壁脂质代谢な及ぼすglycyrrhizinの影响[J].勤脉硬化,1984,12 (4)： 817.
[131]傅乃武,刘朝阳,张如意,等.G9315抗促癌和抑制促癌物诱发的脂质过氧化作用[J].中草药,1995,26(8)：411-413.
[132]程安玮,金征宇,万发春,等.甘草多糖对小鼠腹腔巨噬细胞化学成分及胞内酶的影响[D].北京：中国科学院上海冶金研究所材料物理与化学(专业)博士论文,2000.
[1]杨鹏远,芮耀诚,焦亚斌.动脉粥样硬化大鼠实验模型的建立[J].第二军医大学学报,2003,24(7)：802-804
[2]ROSS R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med,1999,340(2): 115-126.
[3]李建军.炎症与动脉粥样硬化[J].中国医学前沿杂志,2011,3(5)：4-6.
[4]周慧,邓时慧.炎症与动脉粥样硬化的关系[J].中国医药指南,2008,6(5)：61-63.
[5]周永刚,蓝晓红,李祥,等.动脉粥样硬化大鼠实验模型的建立与评价[J].解放军药学学报,2011,27(5)：399-403.
[6]褚现明,李冰,安毅,等.炎症与动脉粥样硬化关系研究进展[J].中国分子心脏病学杂志,2010,11(3)：184-187.
[7]周小波,吴慧琴,张雪梅,等.血管内皮炎症与动脉粥样硬化[J].中国心血管病研究,2008,6(4)：308-309.
[1]缪薇.动脉粥样硬化发病机制和药物干预的研究现状[J].医学综述,2009,15(3)：401-404.
[2]黄敏,周洪莲,杨菲,等.血清氧化低密度脂蛋白抗体水平与动脉粥样硬化危险性的关系[J].临床内科杂志,2008,25(9)：636-637.
[3]ParkYM, Febbraio M, Silverstein RL.CD36 modulates macrophage spreading and migration in response to oxidized low-density lipoprotein[J].Arterioscler Thromb Vase Biol,2007,27:E56-E56.
[4]Yano M, Matsumura I, Senokuehi T, et al.Troglitazone inhibits low-density lipoprotein-induced Macrophage proliferation:Impact of the suppression of nuclear translocation of ERK1/2[J].Atherosclerosis,2007,191:22-23
[5]Park YM, Febbraio M, Silverstein RL.CD36 modulates migration of mouse and human macrophages in response to Oxidized LDL and may contribute to Macrophage trapping in the arterial intima[J] J Clin Investig,2009,119:136-145.
[6]郑莲星.氧化低密度脂蛋白在血管平滑肌细胞增殖过程中对血小板源性生长因子的作用[J].心血管病学进展,2008,29(6)：964-966.
[7]闫凤,陈压西,赵长海.慢性炎症与动脉粥样硬化关系的研究进展[J].现代生物医学进展,2011,11(20)：3964-3967.
[8]Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis?Do the antioxidant trials conducted to date refute the hypothesis?[J].Circulation,2002,105 (17):2107-2111
[1]Aird WC.Endothelial cell heterogeneity and atherosclerosis[J].Curr Atheroscler Rep, 2006,8(1):69-75.
[2]Galkina E, Ley K.Immune and inflammatory mechanisms of atherosclerosis[Jj.Annu Rev Immunol,2009; 27(1):165-97.
[3]饶丹,姜红,曾秋棠.黏附分子细胞间黏附分子-1／E-选择素与冠心病[J].心血管病学进展,2005,26(3)：278-281.
[4]Singh RJ, Mason JC, Lidington EA, et al.Cytokine stimulated vascular cell adhesionmolecule-1 (VCAM-1) ectodomain release is regulated byTIMP-3[J].Cardiovasc Res,2005,67(1):39-49.
[5]Zhang YM(张玉梅),Liu Y (刘颖),et al.Soy is flavones inhibits gene expression of intercellular adhesion molecule-1 and vascular cell adhesionMolecule-1 in aorta vessel of atherosclerotic rat.Chin J Arter(中国动脉杂志),2003,11：13-16.
[6]Kaufmann BA, Sanders JM, Davis C, et al.Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1[J].Circulation,2007; 116(3):276-84.
[7]Rueda-Clausen CF. Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects[J].Mediators Inflamm,2009; 23 (4):469-79.
[8]Matheny HE, Deem TL, Cook-Mills JM.Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endo-thelial cell NADPH oxidase[J].J Immunol,2000; 164(12):6550-9.
[9]Davies MJ, Gordon JL, GearingA J, et al.The expression of the adhesionmolecules ICAM-1, VCAM-1, PEC AM, and E-selectin in human atherosclerosis [J].J Pathol, 1993,171 (3):223-229.
[10]Zhu LQ, Wang SR, Qin Y.Effects of huoxue injection on the adherence of human monocytes to endothelial cells and expression of vascular cell adhesion molecules[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2009,29(3):238-41.
[1]Stoll G, Bendszus M.Inflammation and atherosclerosis:novel insights into plaque formation and destabilization[J].Stroke,2006,37 (7):1923-1932.
[2]Getz GS.Thematic review series:the immune system and atherogene-sis-immune function in atherogenesis[J]J Lipid Res,2005,46 (1):1-10.
[3]Tadamitsu Kishimoto.Interleukin-6:discovery of a pleiotropic cytokine, Arthritis Research&Therapy,2006,8 (Suppl2):52.
[4]Mikko M, Fredriksson K, Wahlstrom J, et al.Human T cells stimulate fibroblast-mediated degradation of extracellular matrix in vitro.Clin Exp Immunol, 2008,1513:17-25.
[5]Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis:a comprehensive review of studies in mice.Cardiovasc Res,2008,79 (3):360-376.
[6]Maier W, Altwegg L A, Corti R, et al.Inflammatory markers at the site of ruptured plaque in acute myocardial infarction:locally increased inter-leukin-6 and serum amyloid Abut decreased C-reactive protein[J].Circulation,2005,111 (11):1355-1361.
[7]齐峰,杨丽霞,郭瑞威,等.冠心病患者血清IL-1β和IL-6含量与冠脉病变的关系[J].心血管康复医学杂志,2008,17(5)：466-489.
[1]Hansson GK, Robertson AK, and Soderberg-Naueler C.Inflammation and Atherosclerosis[J]..Annu RevPatholMechDis,2006,1:297-329.
[2]Lutgens E, Daemen MJ.CD40-CD40L interactions in atherosclerosis[J].Trends Cardiovasc Med,2002,12:27-32.
[3]Cholette JM, Blumberg N, Phipps RP, et al.Developmental changes in soluble CD40 ligand [J].J Pediatr,2008,152 (1):50-54.
[4]ZhuW, Mix E, Jin T, et al.B cells play a cooperative role viaCD40L-CD40 interaction in T cell-mediated experimental autoimmune neuritis in Lewis rats [J].Neurobiol Dis, 2007,25 (3):642-648.
[5]Acuto O, Miehel F.CD28-mediated costimulation:a quantitative support for TCR signalling[J].Nature Rev Immunol,2003,3:939-951.
[6]Pearson TA, Mensah GA, Alexander RW, et al.Markers of inflammation and cardiovascular disease:application to clinical and public health practice:A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J].Circulation,2003,107:499-511.
[7]严金川,杨萍,徐良洁,等.SiRNA阻断CD40-CD40L对ApoE-/-小鼠动脉粥样硬化斑块形成的影响[J].江苏大学学报(医学版),2010,20(4)：296-298.
[8]王静华,丁素菊,邓本强,等.颈动脉粥样硬化斑块CD40、MMP9的表达及意义[J].第二军医大学学报,2008,29(9)：1065-1068.
[9]Turker S, Guneri S, Akdeniz B, et al.Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patientswith stable coronary artery disease[J].Am J Cardiol,2006,97 (2):198-202.
[1]Koerig W.Inflammation and coronary heart disease:an overview[J].Cardiol Rev,2001, 9 (1):31-35.
[2]Yu H, Rifin N.High sensitivity CRP and atherosclerosis, from theory to therapy clinic[J].Biochemistry,2000,33 (8):601-610.
[3]Albert MA, Ridker PM.The role of CRP in cardiovascular disease risk[J].Curr Cardiol Rep,1999,1 (2):99-104
[4]Szalai AJ.The biological functions of C-reactive protein[J].Vasc Pharmacol,2002,39: 105-107.
[5]Yasojima K, Schwab C, McGeer EG, et al.Generation of C-reactive protein and complement components in atherosclerotic plaques[J].2001,158 (3):1039-51.
[6]Tsimikas S, Willerson JT, Ridker PM.C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients[J].J Am Coll Cardiol.2006,47:019-031.
[7]Nakagomi A, Freedman SB, Geczy CL.Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein:relationship with age, sex, and hormone replacement treatment[J].Circulation,2000,101:1785-1791.
[8]王小娟,李军涛.c反应蛋白在不同类型脑梗死患者中的浓度变化分析[J].重庆医学,2008,2(4)：418-419.
[9]武湘云,李立新,李贵霞.脑血管疾病与血清C-反应蛋白关系的探讨[J].临床荟萃,2004,19 (13)： 751.
[10]杨惠聪,吴阿阳,林洁,等.血浆中CRP、Hcy、LDL、HDL含量与动脉粥样硬化的 相关性研究[J].检验医学与临床,2011,8(20)：2433-2437.
[11]Ridker PM, Danielson E, Fonseca F A, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].N Engl J Med,2008,359 (21): 2195-2207.
[1]张先慧,李芳,高晶,等.核因子κB与动脉粥样硬化新进展[J].现代生物医学进展,2008,8(2)：369-371
[2]Chiu JJ, Chen LJ, Chang SF, et al.Shear stress inhibits smooth muscle cell-induced inflammatory gene expression in endothelial cells:role of NF-kappaB [J].Arterioscler Thromb Vasc Bio 1,2005,25 (5):963-969.
[3]胡榕,吴可贵.核因子κB在心血管疾病中作用的研究现状[J].中国动脉硬化杂志,2004,12：604-606.
[4]周俊.核因子-κB与动脉粥样硬化的关系[J].心血管病学进展,2002,23(3)：161-165.
[5]Lee S, Chung J, Ha IS, et al.Hydrogen peroxide increases human leukocyte adhesion to porcine aortic endothelial cells via NF-kappaB-dependent up-regulation of VCAM-1[J].Int Immunol,2007; 19(12):1349-1359
[6]Madge LA, KlugerMS, Orange JS, et al.Lymphotoxin-al-phal, beta2 and light induce classical and noncanonical NF-kappaB-dependent proinflammatory gene expression in vascular endothelial cells[J].J Immunol,2008; 180 (5):3467-3477
[7]Ritchie ME.Nuclear factor-KB is selectively and markedly activated in humans with unstable angina pectoris.Circulation,1998,98(17):1707-1713
[8]李毅,孙瑞红,肖玲,等.MMP-9及NF-κB对人颅内动脉粥样硬化斑块稳定性的影响[J].中风与神经疾病杂志,2009,26(4)：396-398.
[9]王春彬,高大中.高脂血症兔主动脉NF-κB、VCAM-1和VEGF的表达及氟伐他汀的影响[J].中国心血管病研究,2008,6(5)：379-382.
[1]何学令,尹海林.动脉粥样硬化动物模型研究的现状及存在的问题[J].实验动物科学与管理,2006,23(4)：41-44.
[2]陈代钦.鼠动脉粥样硬化模型的研究概况[J].现代医药卫生,2010,26(8)：1173-1174.
[3]陈洁.鼠动脉粥样硬化模型的建立[J].解剖学研究,2007,29(3)：225-227.
[4]Fleckenstein-Grun G, Frey M, Luley C, et al.Differentiation calcium and cholesterol-dominated types of atherosclerosis lesion:antiarteriosclerotic aspects of calcium antagonist[J].Cardiovas Phamacol,1991,18:s1-s9.
[5]Weinstein DB, Heider JG.Antiatherogenic properties of Calcium Antagonists determinants.Am J Cardiol,1987,59:163B-172B.
[6]殷亚昕,刘润梅,翟红霞,等.不同饲料联合维生素D3建立大鼠动脉粥样硬化模型的比较[J].中国康复理论与实践,2010,16(12)：1134-1136.
[1]Braunwald E. Shattuck Lecture 2 Cardiovaseularmedicine at the turn of themillennium: triumphs, ConcerD-s, and opportunities[J]. N Engl J Med,1997,337:1360-1369.
[2]王亚红,郭维琴.动脉粥样硬化中医研究的现状与思路[J].中国医药学报,2002,17(10)：624-625.
[3]马晓昌.陈可冀教授治疗冠心病临床经验介绍——祛浊利湿与活血化瘀并重[J].中西医结合心脑血管病杂志,2005,3(5)：441-442.
[4]陈可冀,马晓昌.关于传统血瘀证的现代分类[J].中国中西医结合杂志,2000,20(7) ： 487.
[5]洪梅,鲁翔,周海波,等.疏血通治疗急性冠脉综合征的疗效[J].江苏医药,2011,37(23)：2867-2868.
[6]高红燕.冠心丹参滴丸与复方丹参片治疗冠心病心绞痛疗效比较[J].临床合理用药,2012,5(1B)：9-10.
[7]刘向敏.脑心通胶囊治疗颈动脉粥样硬化的疗效观察[J].中西医结合心脑血管病杂志,2009,7(5)：627-628.
[8]程小曲.痰浊型冠心病与血脂、脂蛋白、载脂蛋白的关系及痰浊形成机理的探讨[J].新中医.1994,26(3)：7-9.
[9]丁超,王朝亮,.健脾化痰剂治疗高血脂症189例疗效观察[J].中医药临床杂志,2007,19(6)： 581-582.
[10]熊兴江,姚魁武,褚福永,等.王阶辨治血脂异常医案一则[J].中华中医药学会心病分会第十一届学术年会论文集,2009：211-216.
[11]王志强,张学平,张伟,等.化痰通络汤治疗颈动脉内膜粥样硬化斑块临床研究[J].光明中医,2010,25(1)：28-30.
[12]云端,刘建.益气补肾法治疗冠心病不稳定性心绞痛70例[J].四川中医,2010,28(10)：70-71.
[13]蒋晓霞,张斌霞,李小龙.补肾泄浊法治疗颈动脉粥样硬化45例临床观察[J].国医论坛,2006,21(5)：16-17.
[14]李国强,胡业彬.毒邪致动脉粥样硬化的病因病机探讨[J].河南中医,2010,30(12)：1155-1156.
[15]康海静.王化良教授运用清热解毒法治疗冠心病经验[J].长春中医药大学学报,2012,28(1)：59-60.
[16]舒士敏,路娣,张增会,等.复方双花颗粒对冠状动脉粥样硬化性心脏病c-反应蛋白及白细胞计数的影响[J].河北中医,2008,30(2)：126.
[17]吴圣贤,吴雪莲,黄政鑫,等.解毒软脉方抗动脉粥样硬化17例初步临床观察[J].福建中医药,2000,31(5)：8-10.
[18]丁书文,李晓.治疗冠心病的常法与变法[J].中医杂志,2004,45(6)：464-466.
[19]于月罡.针灸治疗冠心病心绞痛60例临床观察[J].中国中医药信息杂志,2008(4)：76-77.
[20]俞文全,许祥贵,吴焕淦.针灸治疗高脂血症的临床研究[J].上海针灸杂志,2011,30(3)：155-157.
[21]高社光,康日新,高莉,等.麝香通痹膏穴位贴敷治疗冠状动脉粥样硬化性心脏病心绞痛130例[J].河北中医,1999,21(3)：136.
[22]毛喜荣,李佩芳,王月兰.穴位注射治疗冠状动脉粥样硬化性心脏病102例的临床观察[J].针灸临床杂志,1995,11(2)：16-18.
[23]杨英,刘斌,毕力夫,等.降脂宁调血脂及抗脂质过氧化作用的实验研究[J]中华中医药杂志,2009,24 (5)：647-649.
[24]邱赛红,李福元,高雁.降脂消斑片对兔高脂血症合并动脉粥样硬化血脂的影响[J].湖南中医药大学学报,2009,29(3)：3.
[25]潘涛,顾勤.血脂清对实验性血脂异常大鼠的降脂及抗动脉粥样硬化作用[J].辽 宁中医杂志,2009,36(12)：2183-2185.
[26]焦宏,杜会博,陈彦静,等.桂枝汤对改善高脂血症心肌缺血大鼠微循环的作用[J].中国动脉硬化杂志,2011,19(12)：984-988.
[27]张斌霞,殷建峰,智瑜.血脉通2号颗粒对动脉粥样硬化鹌鹑血管内皮功能的影响[J].河南中医,2010,30(11)：1066-1067.
[28]季亢挺,唐疾飞,陈鹏,等.丹参素保护内皮祖细胞炎症损伤的机制研究[J].中国预防医学杂志,2010,11(8)：809-812.
[29]张旭静,王素春,范柳,等.当归、川芎、红花、人参萃取液对离体培养牛血管内皮细胞一氧化氮合酶的影响[J].解剖学杂志,2004,27(1)：36.
[30]陈咸川,杨宏杰,陈士明,等.单味当归抑制低密度脂蛋白氧化的方法研究和临床观察[J].上海中医药大学报,2001,15(4)：25.
[31]张军平,许颖智,李明,等.四妙勇安汤对动脉粥样硬化模型兔氧化应激及炎症反应的影响[J].中医杂志,2010,51(1)：72-74.
[32]赵学军,李任先,刘国普,等.理脾化痰方对食饵性动脉粥样硬化症家兔血管平滑肌细胞增殖和凋亡的调控[J].广州中医药大学学报,2001,18(2)：144-148.
[33]赵君玫,魏群,毕红征,等.淫羊藿甙对动脉粥样硬化家兔血管平滑肌细胞内质网应激的影响[J].中医学报,2010,25(4)：680-682.
[34]王宏伟,赵月华,熊一力,等.API0134对实验性动脉粥样硬化家兔血液凝固性和血栓弹力图的影响.中国动脉硬化杂志,1998,6(2)：109-111.
[35]胡发明,胡红丁.川芎嗪的实验研究及临床应用[J].中医研究,2004,17(3)：57-60.
[36]周宜轩,周磊,吴元杰,等.蓝黄胶囊对动脉粥样硬化家兔调节TXA2与PGI 2平衡的研究[J].中国中医急症,2005,14(4)：347.
[37]张俊峰,高振华,张桂英,等.黄芪、三七有效成分配伍抗动脉粥样硬化作用的实验研究[J].中西医结合心脑血管病杂志,2009,2(7)：2.
[38]王斌,管思明,李西栋.微米复方黄连制剂对高脂饮食喂养家兔核因子-κB及炎症因子表达的影响[J].中国中药杂志,2007, (6)：1207-1210.
[39]姜萍,李晓.中药调心饮对家兔动脉粥样硬化冠脉微血管密度及心肌NF-κB表达 的影响[J].中国微循环,2005, (4)：245-247.
[2]李国强,胡业彬.毒邪致动脉粥样硬化的病因病机探讨[J].河南中医,2010,30(12)：1155-1156.
[3]吴天敏,杜建.中医药抗动脉粥样硬化的研究概况[J].福建中医学院学报,2006,16(3)：67-69.
[4]张艳,杨关林,于睿,等.动脉粥样硬化中医虚瘀痰毒病因病机实质研究探讨[J].时珍国医国药,2007,18(6)：1513-1514.
[5]董美玲,徐云生.从脾胃论治冠心病[J].贵阳中医学院学报,2009,31(6)：7-9.
[6]程小曲.痰浊型冠心病与血脂、脂蛋白、载脂蛋白的关系及痰浊形成机理的探讨[J].新中医.1994,26(3)：7-9.
[7]张京春,陈可冀.瘀毒病机与动脉粥样硬化易损斑块相关的理论思考[J].中国中西医结合杂志,2008,28(4)：366-368.
[8]徐浩,史大卓,殷惠军,等.“瘀毒致变”与急性心血管事件：假说的提出与临床意义[J].中国中西医结合杂志,2008,28(10)：934-938.
[9]马晓昌,尹太英,陈可冀,等.冠心病中医辨证分型与冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(9)：654-656.
[10]张勤,崔晓萍,贾晓东.活血化瘀中药治疗动脉粥样硬化的研究进展[J].中医学报,2009,24(5)：126-127.
[11]邵致格.现代人群的体质病理学特征：气虚血瘀[J].医学与哲学,2005,26(4)：74-75.
[12]林代华.气虚血瘀是冠心病的病机关键释义[J].中医药学刊,2003,21(4)：588-589.
[13]刘洪.气虚血瘀证与血管内皮细胞相关因子的研究进展[J].中国中医基础医学杂志,2005,11(7)：553-556.
[14]林培政,杨开清.动脉粥样硬化中医湿热病机再认识[J].新中医,2006,38(3)：5-6.
[15]林培政,杨开清.动脉粥样硬化性疾病与中医湿热证的关系[J].中药新药与临床药理,2006,17(2)：147-149.
[16]陈浩,胡业彬.冠心病某些危险因素与“瘀毒”病因关系探讨[J].安徽中医学院学报,2009,28(4)：3-5.
[17]蔡云海.从热毒观念论治冠心病[J].光明中医,2009,24(5)：798-799.
[18]吴伟,彭锐.冠心病热毒病机的探讨[J].新中医,2007,39(6)：3-4.
[19]丁书文,李晓,李运伦.热毒学说在心系疾病中的构建与应用[J].山东中医药大学学报,2004,28(6)：413-416.
[20]王少英.清热解毒药物在治疗冠心病中的运用[J].北京中医,2004,23(1)：14.
[21]李建军.炎症可能是连接高血压和动脉粥样硬化的桥梁[J].中国分子心脏病学杂志,2005,5(1)：385-388.
[22]Koea, Amrif, Pandey NR, et al.Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation:evidence from m-CSF-deficient mice[J].Am J Physiol Heart Circ Physiol,2007,293 (4): H1789-H1795.
[23]Watson T, Goon PK, Lip GY.Endothelial progentor cells, endothelia ldsyfunction, inflammation, and oxidative stress in hypertension[J].Antioxid Redos Signal,2008, 10 (6):1079-1088
[24]Maya E, Redecke B, Gruner S, et al.Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice[J].Arterioscler Thromb Vasc Biol,2003,23(5):789-794.
[25]Ibrahim AI, Obeid MT, Jouma MJ, et al.Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaues and in unaffected bypass grafts[J].J Clin Virol,2005,32(1):29.
[26]孙余华,襄卫东.炎症与动脉粥样硬化基础和临床研究的新进展[J].中国循环杂志,2003,18(3)：232-235.
[27]Smith CJ, Fisher TH.Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction[J].Atherosclerosis,2001,158(2):257-267.
[28]MuCully, KS.Vascular pathology of homocysteinemia:implications for the pathogenesis of arteriosclerosis[J].Am J Pathol,1969,56:111-128.
[29]R Clarke, L Daly, K Robinson, et al.Hyperhomocysteinemia:an independent risk factor for vascular disease[J].N.Engl.J.Med, Apr 1991,324:1149-1155.
[30]SC Guba, LM Fink, and V Fonseca.Hyperhomocysteinemia.An emerging and important risk factor for thromboembolic and cardiovascular disease[J].Am J Clin Pathol,1996,106 (6):709-722.
[31]Goldbourt U, Neufeld HN. Genetic aspects of arteriosclerosis[J]. Arteriosclerosis, 1988,6:357-377.
[32]张运.动脉粥样硬化研究的当前问题[J].中国医药科学,2012,2(1)：9-11.
[33]McPherson R, Pertsemlidis A, Kavaslar N, et al.A common allele on chromosome 9 associated with coronary heart disease[J].Science, Jun 8 2007,3 16(5830):1488-1491.
[34]Schunkert H, Gotz A, Braund P, et al.Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease[J].Circulation,2008,117(13):1675-1684.
[35]Skaln K, Gustafsson M, Rydberg EK, et al.Subendothelial retention of atherogenic lipoproteins in early atherosclerosis[J].Nature,2002,417:750-754.
[36]Gouni-Berthold I, Sachinidis A.possible non-classic intracellular and molecular mechanism of LDL cholesterol action contributing to the development and progression of atherosclerosis[J].Curr vasc pharmacol,2004,2(4):363-70.
[37]Sheen AJ, Kulbertus H.Chinese study of the month.REVERAL and PROVE-IT: confirmation of the concept"the lower, the better"for cholesterol therapy in patients with coronary heart disease[J].[article in French]Rev Med Liege,2004,59(3):167-73.
[38]Olkkonen VM, Lehto M.Oxysterols and oxysterol binding proteins:role in lipid metabolism and atherosclerosis.Ann Med,2004,36 (8):562-572.
[39]Libby P.Molecular bases of the acute coronary syndromes[J].Circulation,1995,91: 2844-2850.
[40]WILSON AM, RYAN MC, BOYLE AL-The novel role of C-reactive protein in cardiovascular disease:risk maker or pathogen[J].Int J Cardiol,2006,106(3):291-297.
[41]Pasceri V, Chang J, Willerson JT, et al.Modulation of c-reactive protein-mediated monocyte chemoattractant protein-1 induction in humman endothelial cells by anti-atherosclerosis drugs[J].Circulation,2001,103(21):2531-2534.
[42]Verma S, Li SH, Badiwala MV, et al.Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein[J].Circulation, 2002,105 (16):1890-1896.
[43]Verma S, Wang CH, Li SH, et al.A self-fulfilling prophecy:C-reactive protein attenuates nitric oxide production and inhibits angiogenesis[J].Circulation,2002,106 (8):913-919.
[44]Venugopal SK, Devaraj S, Yuhanna I, et al.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells[J].Circulation,2002,106(12):1439-1441.
[45]Zwaka TP, Hombach V, Torzewski J.C-reactive protein-mediated low density lipoprotein uptake by macrophages:implicatios for atherosclerosis[J].Circulation, 2001,103 (9):1194-1197.
[46]Yeh ET, Anderson HV, Pasceri V, et al.C-reactive protein:linking inflammation to cardiovascular complications[J].Circulation,2001,104(9):974-975.
[47]何玉辉,刘惠亮.粘附分子与动脉粥样硬化关系的研究进展[J].疑难病杂志,2006,5(2)： 155-157.
[48]Poston RN, Haskard DO, Coucher JR, et al.Expression of intercellular adhesionmolecule-linatheroscleroticplaques[J].Am J Pathol,1992,140:665-673.
[49]Printeseva OY, Peclo MM, Goron AM.Various cell type in human atherosclerotic lesions express ICAM-1:Further immunocytochemical and immunochemical studies employing monoclonal antibody10F3[J].Am J Pathol,1992,140:896-899.
[50]Wu YQ, Zhang RJ, Zhou CH, et al.Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice [J].Atherosclerosis,2009,203 (2): 360-370.
[51]Li JJ, Li YS, Hui RT, et al.Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin-10 in patients with unstable angina[J].Heart,2006,92 (4):529-530.
[52]Flavia S, Francesca M, Mariapaola M, et al.IL-6-deficient mice showimpaired inflammatory response in a model of myosin induced experimental myositis[J].Journal of Neuroimmunology,2006,176(1-2):9-15.
[53]Ishai L, Ronni G, David P, et al.Elevated levels of CRP in ovarian hyperstimulation syndrome:an unrecognised potential hazard[J].BJOG,2005,112(7):952-955.
[54]Pau E, Alonso-Muriel I, Gomez R, et al.Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome[J].Hum Reprod,2006,21 (6):1453-1460.
[55]Harrington JR.The role of MCP-1 in atherosclerosis[J].Stem Cells,2000,18(1):65-66.
[56]Deo R, Khera A, Mcguire DK, et al.Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and sub clinical atherosclerosis[J].J Am Coll Cardiol,2004,44(9):1812-1818.
[57]Taleb S, Herbin O, Ait-Oufella H, et al.Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protectsmice from atherosclerosis[J].A rterioscler Thromb Vasc Biol,2007,27(12):2691-2698.
[58]Valentina C, Daniel N, Barbara ND, et al.CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure [J]. Atherosclerosis, 2007,190 (1):156-166.
[59]Xia M, Ling WH, Zhu HL, et al.Anthocyanin attenuates CD40-mediated endothelial cell activation and apoptosis by inhibiting CD40-induced MAPK activation[J].Atherosclerosis,2009,202 (1):41-47.
[60]JawienJ, Gajda M, Mateuszuk, et al.Inhibition ofnuclear factor-kpaB attenuates artherosclerosis in apoE/LDLR-double knockoutmice [J].Physiol Pharmacol,2005,56 (3):483-489.
[61]Lwaleed BA, Cooper AJ, Voegeli D, et al.Tissue factor:a critical role in inflammation and cancer[J].Biol Res Nurs,2007,9(2):97-107.
[62]Chu AJ.Role of tissue factor in thrombosis.Coagulation inflammation-thrombosis circuit[J].Front Biosci,2006,11:256-271.
[63]Skaln K, GustafssonM, RydbergE K, et al.Subendothelial retention of atherogenic lipoproteins in early atherosclerosis[J].Nature,2002,417:750-754.
[64]Waters DD, LaRosa JC, Barter P, et al.Effects of high-dose atorvastatin on erebrovascular events in patients with stable cornaary disease in the TNT (Treating to New Targets) Study [J].J Am Coll Cardiol,2006,48:1793-1799.
[65]Pedersen TR, Faerqueman O, Kastelein JJ, et al.High-dose atorva statin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study a randomized controlled trial [J]. JAM A,2005,294:2437-2445.
[66]中华医学会心血管病学分会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-419.
[67]Amarenco P, Bogousslavsky J, Callahan A, et al.The stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators high-dose atorvastatin afterstroke or transient is chemic attack[J].N Eng J Med,2006,355:549-559.
[68]赵志刚.抗动脉粥样硬化药物分类及研究进展[J].Chin J Arterioscler,2005, 13 (S1):52-56.
[69]中华医学会心血管病学分会等。正确认识合理使用调脂药物[J].中华心血管杂志,2001,29(12)：705-706.
[70]王素香,王拥军,尹洪超,等.PAS综合疗法对兔动脉粥样硬化的干预[J].中国动脉硬化杂志,2007,15(7)：542-543.
[71]曹剑,朱冰坡.普罗布考对老年下肢动脉硬化症的抗氧化和抗炎症作用[J].中国动脉硬化杂志.2006,14：336-338.
[72]严鹏科,廖端芳,杨永宗.普罗布考对巨噬细胞分泌基质金属蛋白酶9的抑制作用[J].中国动脉硬化杂志.2003,11：199-202.
[73]陈康寅,黄体钢.钙拮抗药在抗高血压治疗中的应用[J].中国现代神经疾病杂志,2007,7(2)：175-179.
[74]Harda SM, Kinoshita M, Kamido H, et al Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms[J].J Biol Chem,1998,273(16):9681-9687.
[75]Nichol KL, Nordin J, Mullooly J, et al.Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly[J].N Engl J Med, 2003,348 (14):1322-1332.
[76]张子新,赵卫华,宋丽新,等.阿奇霉素对动脉粥样硬化家兔炎症反应的影响[J].中国动脉硬化杂志,2006,14(7)：601-603.
[77]贾孟辉,于晓宁,贺晓慧.桃核承气汤加味治疗高脂血症43例疗效观察[J].宁夏医学院学报,2008,30(2)：249-251.
[78]杨丁友,马路,段学忠.桃核承气胶囊治疗高半胱氨酸血症40例[J].中医杂志,2003,44(6)：445-446.
[79]崔昕.桃核承气汤对多发性脑梗塞患者的疗效[J].国外医学·中医中药分册,1996,18(2)： 24-25.
[80]黄俊臣,周纪平,李彦春.核桃承气汤对脑梗死急性期辅助治疗作用的观察[J]. 安徽中医临床杂志,2003,15(4)：280.
[81]黎裕朝.小陷胸汤治疗冠心病28例[J].国医论坛,1999,14(6)：9.
[82]李景君,王蕊,徐京育.加味小陷胸汤治疗不稳定型心绞痛临床观察[J].中医药学报,2010,38(2)：123-124.
[83]孔秀英.小陷胸汤加味治疗冠心病心绞痛78例[J].中国中医急症,2008,17(5)：685.
[84]左建国.加味小陷胸汤联合辛伐他汀治疗高脂血症疗效观察[J].广东医学,2010,31(14)：1878-1880.
[85]路辉,王妍岩,袁春英.小陷胸汤加减治疗室性早搏60例[J].武警医学,1998,9(8)：453-454.
[86]高鸿,李厚根.小陷胸汤加减治疗病理性短阵室速32例[J].实用中医内科杂志,1999,13(1)： 44.
[87]刘东方,倪约翰.小陷胸汤对痰热蕴结型心悸的临床观察[J].中医药信息,2010,27(6)：19-21.
[88]万远铁,高春华,查丽.泻心通腑法治疗中风病162例疗效观察[J].湖北中医杂志,1991,13(4)：8-9.
[89]秦增祥.大黄黄连泻心汤药理和应用[J].中成药,1995,17(12)：39.
[90]泉正夫[日].三黄泻心汤胶囊治验一例及其考察[J].汉方研究,1991,(4)：14.
[91]赵雷,朱亮,钱义明,等.泻心汤配合西医常规治疗急性冠脉综合征20例炎性指标变化的观察[J].中医药导报,2008,14(7)：15-17.
[92]唐阿方.泻心胶囊治疗火邪热结型冠心病心绞痛的临床研究[D].长沙：湖南中医学院,2005.
[93]谢华,马越鸣,等.桃核承气汤对动物血栓形成及血小板聚集的影响[J].中成药,2006,11(28)：1631-1634.
[94]何赛萍,徐晓东,等.桃核承气汤对热瘀大鼠模型血液流变学和凝血指标的影响[J].浙江中医学院学报,2003,6(27)：56-57.
[95]喻秀兰,梅国强,张德玲,等.小陷胸汤加味含药血清对人脐静脉内皮细胞分泌NO／ET-1的调节作用[J].微循环学杂志,2005,15(2)：41-42.
[96]喻秀兰,梅国强,张德玲,等.加味小陷胸汤对氧化低密度脂蛋白致血管内皮细胞增殖和凋亡的影响[J].湖北中医学院学报,2005(7)2：6-7.
[97]郭志清,刘奇龙.小陷胸汤加味方对兔心肌缺血再灌注损伤MDA、SOD和CK-MB的影响[J].中国中医急症,2009,18(12)：2020-2021.
[98]吴智春,吴凯,王浩,等.金匮泻心汤抗动脉粥样硬化的实验研究[J].中国老年学杂志,2003,23(7)：461-462.
[99]王健,孙秀梅,张兆旺.大黄黄连泻心汤研究[J].中国现代医药,2005,4(6)：16-17.
[100]黄兆胜主编.全国高等中医药院校教材·中药学[M].北京：人民卫生出版社,2002： 137.
[101]郭志伟,刘琳娜.大黄及其有效成分的药理研究概况[J].中国药房,2006,17(22)： 1742.
[102]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响[J].中国中西医结合杂志,2005,25(4)：345.
[103]邓杰,王明明,方国安,等·大黄对脑创伤患者血清细胞因子的早期影响[J].中国临床药学杂志,2006,15(1)：50.
[104]侯家玉.中药药理学[M].北京：中国中医药出版社,2002：506.
[105]黄河清,刘培庆,黑子清,等.家兔实验性动脉粥样硬化时主动脉鞘磷脂酶活性与神经酰胺含量变化及大黄素的影响[J].中国病理生理杂志,2004,20(12)：2223-2226.
[106]潘浩,刘学波,张红旗,等.大黄素对人血管平滑肌细胞增殖的影响[J].解剖学研究,2004,26(2)：121.
[107]花拉,白茹玉,刘永喜.蒙药大黄药理研究进展[J].内蒙古民族大学学报,2007,22(1)： 80.
[108]姚文兵,陈琼华·大黄的生化学研究XXXIV波叶大黄多糖的抗血栓和强心作用[J].生化药物杂志,1991,1：42.
[109]于晓东.崔金海应用大黄治疗急性中风病经验[J].河北中医,2006,28(1)：5.
[110]段浩,张宏考,刘继军,等.小檗碱对兔颈动脉损伤后白介素-6等的影响[J]. 医药论坛杂志,2006,27(10)：6-9.
[111]HONG Y, HUI SC, CHAN TY, et al.Effect of betherine on regression of pressure overload induced cardiac hypertrophy in rats[J].Am J Chinese Micine,2002,30 (4): 588-599.
[112]易屏,陆付耳,陈广,等.小檗碱抑制核因子NF-κ Bp65表达及转位改善游离脂肪酸诱导的3T3-L1细胞胰岛素抵抗的分子机制[J].中国中西医结合杂志,2007,12(12)：1099-1103.
[113]吴迪,范明松,李志雄.小檗碱对心血管药理作用的研究进展[J].中国医药指南,2012,10(1)： 61-62.
[114]Liu IX, Durham DG, Richards RM.Baicalin synergy with beta-lactam antibiotics against methicillin-resistantStaphylococcus aureus and other beta-lactam-resistant strains of Saureus[J].J Pharm Pharmacol,2000,52(3):361-366.
[115]侯家玉.中药药理学[M].北京：中国中医药出版社,2002：80
[116]李敏,杨瑞芳.黄芩药理学研究进展综述[J].临床和实验医学杂志,2009,8(1)：137-138.
[117]Park WH, Shin SS, Lee YC, et al. The inhibitory effects of Silso-San-Gami-on atherosclerosis in KHC rabbits [J]. Thrornb Res,2004,113(34):235.
[118]耿涛,谢梅林,彭少平.桃仁提取物抗大鼠心肌缺血作用的研究[J].苏州大学学报,2005,25(2)：238.
[119]王新胜,吴艳芳,马军营,等.半夏化学成分和药理作用研究[J].齐鲁药事,2008,27(2)： 101-103.
[120]韩太云,王桂照,孟繁超,等.中药半夏提取物杭心律失常作用的实验研究[J].哈尔滨医科大学学报.1985,19(3)：75-77.
[121]腾守志,王桂照,付世英,等.半夏浸液杭心律失常的实验研究[J].中华心血管病杂志,1983,11(2)：103.
[122]洪往球,沃行德,何一中,等.半夏降血脂作用研究仁[J].浙江中医学院学报,1995,19(2)：28-29.
[123]刘进杨,杨志明,谭友庄.掌叶半夏碱乙对实验性血栓形成的影响[J].北京医药 工业,1984,(2)：13.
[124]沈雅琴,张明发,朱自平,等.半夏的抗腹泻和抗炎作用[J].中药药理与临床,1998,14(2)：29-31.
[125]张弢,沈文芳,朱俊.瓜蒌对心血管系统的药理作用及临床应用[J].中国乡村医药杂志,2007,14(11)：52.
[126]凌红.瓜蒌、心得安对血小板体外集聚和TXA2合成的影响[J].湖北医学院学报,1988,9 (2)： 138.
[127]上海市化工“七·二一”工人大学有机系中草药组.栝楼研究III,栝楼有效成分的研究初报-有效部位分离、药理及临床观察[J].医药工业,1975,(1)：15.
[128]李自成,常青.瓜蒌注射液对兔血管平滑肌细胞增殖细胞核抗原表达的影响[J].中国病理生理杂志,2000,16(6)：516-518.
[129]滕勇荣,王连侠,张永清.瓜蒌药理研究进展[J].齐鲁药事,2010,29(7)：417-419.
[130]志气保子.动脉壁脂质代谢な及ぼすglycyrrhizinの影响[J].勤脉硬化,1984,12 (4)： 817.
[131]傅乃武,刘朝阳,张如意,等.G9315抗促癌和抑制促癌物诱发的脂质过氧化作用[J].中草药,1995,26(8)：411-413.
[132]程安玮,金征宇,万发春,等.甘草多糖对小鼠腹腔巨噬细胞化学成分及胞内酶的影响[D].北京：中国科学院上海冶金研究所材料物理与化学(专业)博士论文,2000.
[1]杨鹏远,芮耀诚,焦亚斌.动脉粥样硬化大鼠实验模型的建立[J].第二军医大学学报,2003,24(7)：802-804
[2]ROSS R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med,1999,340(2): 115-126.
[3]李建军.炎症与动脉粥样硬化[J].中国医学前沿杂志,2011,3(5)：4-6.
[4]周慧,邓时慧.炎症与动脉粥样硬化的关系[J].中国医药指南,2008,6(5)：61-63.
[5]周永刚,蓝晓红,李祥,等.动脉粥样硬化大鼠实验模型的建立与评价[J].解放军药学学报,2011,27(5)：399-403.
[6]褚现明,李冰,安毅,等.炎症与动脉粥样硬化关系研究进展[J].中国分子心脏病学杂志,2010,11(3)：184-187.
[7]周小波,吴慧琴,张雪梅,等.血管内皮炎症与动脉粥样硬化[J].中国心血管病研究,2008,6(4)：308-309.
[1]缪薇.动脉粥样硬化发病机制和药物干预的研究现状[J].医学综述,2009,15(3)：401-404.
[2]黄敏,周洪莲,杨菲,等.血清氧化低密度脂蛋白抗体水平与动脉粥样硬化危险性的关系[J].临床内科杂志,2008,25(9)：636-637.
[3]ParkYM, Febbraio M, Silverstein RL.CD36 modulates macrophage spreading and migration in response to oxidized low-density lipoprotein[J].Arterioscler Thromb Vase Biol,2007,27:E56-E56.
[4]Yano M, Matsumura I, Senokuehi T, et al.Troglitazone inhibits low-density lipoprotein-induced Macrophage proliferation:Impact of the suppression of nuclear translocation of ERK1/2[J].Atherosclerosis,2007,191:22-23
[5]Park YM, Febbraio M, Silverstein RL.CD36 modulates migration of mouse and human macrophages in response to Oxidized LDL and may contribute to Macrophage trapping in the arterial intima[J] J Clin Investig,2009,119:136-145.
[6]郑莲星.氧化低密度脂蛋白在血管平滑肌细胞增殖过程中对血小板源性生长因子的作用[J].心血管病学进展,2008,29(6)：964-966.
[7]闫凤,陈压西,赵长海.慢性炎症与动脉粥样硬化关系的研究进展[J].现代生物医学进展,2011,11(20)：3964-3967.
[8]Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis?Do the antioxidant trials conducted to date refute the hypothesis?[J].Circulation,2002,105 (17):2107-2111
[1]Aird WC.Endothelial cell heterogeneity and atherosclerosis[J].Curr Atheroscler Rep, 2006,8(1):69-75.
[2]Galkina E, Ley K.Immune and inflammatory mechanisms of atherosclerosis[Jj.Annu Rev Immunol,2009; 27(1):165-97.
[3]饶丹,姜红,曾秋棠.黏附分子细胞间黏附分子-1／E-选择素与冠心病[J].心血管病学进展,2005,26(3)：278-281.
[4]Singh RJ, Mason JC, Lidington EA, et al.Cytokine stimulated vascular cell adhesionmolecule-1 (VCAM-1) ectodomain release is regulated byTIMP-3[J].Cardiovasc Res,2005,67(1):39-49.
[5]Zhang YM(张玉梅),Liu Y (刘颖),et al.Soy is flavones inhibits gene expression of intercellular adhesion molecule-1 and vascular cell adhesionMolecule-1 in aorta vessel of atherosclerotic rat.Chin J Arter(中国动脉杂志),2003,11：13-16.
[6]Kaufmann BA, Sanders JM, Davis C, et al.Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1[J].Circulation,2007; 116(3):276-84.
[7]Rueda-Clausen CF. Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects[J].Mediators Inflamm,2009; 23 (4):469-79.
[8]Matheny HE, Deem TL, Cook-Mills JM.Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endo-thelial cell NADPH oxidase[J].J Immunol,2000; 164(12):6550-9.
[9]Davies MJ, Gordon JL, GearingA J, et al.The expression of the adhesionmolecules ICAM-1, VCAM-1, PEC AM, and E-selectin in human atherosclerosis [J].J Pathol, 1993,171 (3):223-229.
[10]Zhu LQ, Wang SR, Qin Y.Effects of huoxue injection on the adherence of human monocytes to endothelial cells and expression of vascular cell adhesion molecules[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2009,29(3):238-41.
[1]Stoll G, Bendszus M.Inflammation and atherosclerosis:novel insights into plaque formation and destabilization[J].Stroke,2006,37 (7):1923-1932.
[2]Getz GS.Thematic review series:the immune system and atherogene-sis-immune function in atherogenesis[J]J Lipid Res,2005,46 (1):1-10.
[3]Tadamitsu Kishimoto.Interleukin-6:discovery of a pleiotropic cytokine, Arthritis Research&Therapy,2006,8 (Suppl2):52.
[4]Mikko M, Fredriksson K, Wahlstrom J, et al.Human T cells stimulate fibroblast-mediated degradation of extracellular matrix in vitro.Clin Exp Immunol, 2008,1513:17-25.
[5]Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis:a comprehensive review of studies in mice.Cardiovasc Res,2008,79 (3):360-376.
[6]Maier W, Altwegg L A, Corti R, et al.Inflammatory markers at the site of ruptured plaque in acute myocardial infarction:locally increased inter-leukin-6 and serum amyloid Abut decreased C-reactive protein[J].Circulation,2005,111 (11):1355-1361.
[7]齐峰,杨丽霞,郭瑞威,等.冠心病患者血清IL-1β和IL-6含量与冠脉病变的关系[J].心血管康复医学杂志,2008,17(5)：466-489.
[1]Hansson GK, Robertson AK, and Soderberg-Naueler C.Inflammation and Atherosclerosis[J]..Annu RevPatholMechDis,2006,1:297-329.
[2]Lutgens E, Daemen MJ.CD40-CD40L interactions in atherosclerosis[J].Trends Cardiovasc Med,2002,12:27-32.
[3]Cholette JM, Blumberg N, Phipps RP, et al.Developmental changes in soluble CD40 ligand [J].J Pediatr,2008,152 (1):50-54.
[4]ZhuW, Mix E, Jin T, et al.B cells play a cooperative role viaCD40L-CD40 interaction in T cell-mediated experimental autoimmune neuritis in Lewis rats [J].Neurobiol Dis, 2007,25 (3):642-648.
[5]Acuto O, Miehel F.CD28-mediated costimulation:a quantitative support for TCR signalling[J].Nature Rev Immunol,2003,3:939-951.
[6]Pearson TA, Mensah GA, Alexander RW, et al.Markers of inflammation and cardiovascular disease:application to clinical and public health practice:A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J].Circulation,2003,107:499-511.
[7]严金川,杨萍,徐良洁,等.SiRNA阻断CD40-CD40L对ApoE-/-小鼠动脉粥样硬化斑块形成的影响[J].江苏大学学报(医学版),2010,20(4)：296-298.
[8]王静华,丁素菊,邓本强,等.颈动脉粥样硬化斑块CD40、MMP9的表达及意义[J].第二军医大学学报,2008,29(9)：1065-1068.
[9]Turker S, Guneri S, Akdeniz B, et al.Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patientswith stable coronary artery disease[J].Am J Cardiol,2006,97 (2):198-202.
[1]Koerig W.Inflammation and coronary heart disease:an overview[J].Cardiol Rev,2001, 9 (1):31-35.
[2]Yu H, Rifin N.High sensitivity CRP and atherosclerosis, from theory to therapy clinic[J].Biochemistry,2000,33 (8):601-610.
[3]Albert MA, Ridker PM.The role of CRP in cardiovascular disease risk[J].Curr Cardiol Rep,1999,1 (2):99-104
[4]Szalai AJ.The biological functions of C-reactive protein[J].Vasc Pharmacol,2002,39: 105-107.
[5]Yasojima K, Schwab C, McGeer EG, et al.Generation of C-reactive protein and complement components in atherosclerotic plaques[J].2001,158 (3):1039-51.
[6]Tsimikas S, Willerson JT, Ridker PM.C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients[J].J Am Coll Cardiol.2006,47:019-031.
[7]Nakagomi A, Freedman SB, Geczy CL.Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein:relationship with age, sex, and hormone replacement treatment[J].Circulation,2000,101:1785-1791.
[8]王小娟,李军涛.c反应蛋白在不同类型脑梗死患者中的浓度变化分析[J].重庆医学,2008,2(4)：418-419.
[9]武湘云,李立新,李贵霞.脑血管疾病与血清C-反应蛋白关系的探讨[J].临床荟萃,2004,19 (13)： 751.
[10]杨惠聪,吴阿阳,林洁,等.血浆中CRP、Hcy、LDL、HDL含量与动脉粥样硬化的 相关性研究[J].检验医学与临床,2011,8(20)：2433-2437.
[11]Ridker PM, Danielson E, Fonseca F A, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].N Engl J Med,2008,359 (21): 2195-2207.
[1]张先慧,李芳,高晶,等.核因子κB与动脉粥样硬化新进展[J].现代生物医学进展,2008,8(2)：369-371
[2]Chiu JJ, Chen LJ, Chang SF, et al.Shear stress inhibits smooth muscle cell-induced inflammatory gene expression in endothelial cells:role of NF-kappaB [J].Arterioscler Thromb Vasc Bio 1,2005,25 (5):963-969.
[3]胡榕,吴可贵.核因子κB在心血管疾病中作用的研究现状[J].中国动脉硬化杂志,2004,12：604-606.
[4]周俊.核因子-κB与动脉粥样硬化的关系[J].心血管病学进展,2002,23(3)：161-165.
[5]Lee S, Chung J, Ha IS, et al.Hydrogen peroxide increases human leukocyte adhesion to porcine aortic endothelial cells via NF-kappaB-dependent up-regulation of VCAM-1[J].Int Immunol,2007; 19(12):1349-1359
[6]Madge LA, KlugerMS, Orange JS, et al.Lymphotoxin-al-phal, beta2 and light induce classical and noncanonical NF-kappaB-dependent proinflammatory gene expression in vascular endothelial cells[J].J Immunol,2008; 180 (5):3467-3477
[7]Ritchie ME.Nuclear factor-KB is selectively and markedly activated in humans with unstable angina pectoris.Circulation,1998,98(17):1707-1713
[8]李毅,孙瑞红,肖玲,等.MMP-9及NF-κB对人颅内动脉粥样硬化斑块稳定性的影响[J].中风与神经疾病杂志,2009,26(4)：396-398.
[9]王春彬,高大中.高脂血症兔主动脉NF-κB、VCAM-1和VEGF的表达及氟伐他汀的影响[J].中国心血管病研究,2008,6(5)：379-382.
[1]何学令,尹海林.动脉粥样硬化动物模型研究的现状及存在的问题[J].实验动物科学与管理,2006,23(4)：41-44.
[2]陈代钦.鼠动脉粥样硬化模型的研究概况[J].现代医药卫生,2010,26(8)：1173-1174.
[3]陈洁.鼠动脉粥样硬化模型的建立[J].解剖学研究,2007,29(3)：225-227.
[4]Fleckenstein-Grun G, Frey M, Luley C, et al.Differentiation calcium and cholesterol-dominated types of atherosclerosis lesion:antiarteriosclerotic aspects of calcium antagonist[J].Cardiovas Phamacol,1991,18:s1-s9.
[5]Weinstein DB, Heider JG.Antiatherogenic properties of Calcium Antagonists determinants.Am J Cardiol,1987,59:163B-172B.
[6]殷亚昕,刘润梅,翟红霞,等.不同饲料联合维生素D3建立大鼠动脉粥样硬化模型的比较[J].中国康复理论与实践,2010,16(12)：1134-1136.
[1]Braunwald E. Shattuck Lecture 2 Cardiovaseularmedicine at the turn of themillennium: triumphs, ConcerD-s, and opportunities[J]. N Engl J Med,1997,337:1360-1369.
[2]王亚红,郭维琴.动脉粥样硬化中医研究的现状与思路[J].中国医药学报,2002,17(10)：624-625.
[3]马晓昌.陈可冀教授治疗冠心病临床经验介绍——祛浊利湿与活血化瘀并重[J].中西医结合心脑血管病杂志,2005,3(5)：441-442.
[4]陈可冀,马晓昌.关于传统血瘀证的现代分类[J].中国中西医结合杂志,2000,20(7) ： 487.
[5]洪梅,鲁翔,周海波,等.疏血通治疗急性冠脉综合征的疗效[J].江苏医药,2011,37(23)：2867-2868.
[6]高红燕.冠心丹参滴丸与复方丹参片治疗冠心病心绞痛疗效比较[J].临床合理用药,2012,5(1B)：9-10.
[7]刘向敏.脑心通胶囊治疗颈动脉粥样硬化的疗效观察[J].中西医结合心脑血管病杂志,2009,7(5)：627-628.
[8]程小曲.痰浊型冠心病与血脂、脂蛋白、载脂蛋白的关系及痰浊形成机理的探讨[J].新中医.1994,26(3)：7-9.
[9]丁超,王朝亮,.健脾化痰剂治疗高血脂症189例疗效观察[J].中医药临床杂志,2007,19(6)： 581-582.
[10]熊兴江,姚魁武,褚福永,等.王阶辨治血脂异常医案一则[J].中华中医药学会心病分会第十一届学术年会论文集,2009：211-216.
[11]王志强,张学平,张伟,等.化痰通络汤治疗颈动脉内膜粥样硬化斑块临床研究[J].光明中医,2010,25(1)：28-30.
[12]云端,刘建.益气补肾法治疗冠心病不稳定性心绞痛70例[J].四川中医,2010,28(10)：70-71.
[13]蒋晓霞,张斌霞,李小龙.补肾泄浊法治疗颈动脉粥样硬化45例临床观察[J].国医论坛,2006,21(5)：16-17.
[14]李国强,胡业彬.毒邪致动脉粥样硬化的病因病机探讨[J].河南中医,2010,30(12)：1155-1156.
[15]康海静.王化良教授运用清热解毒法治疗冠心病经验[J].长春中医药大学学报,2012,28(1)：59-60.
[16]舒士敏,路娣,张增会,等.复方双花颗粒对冠状动脉粥样硬化性心脏病c-反应蛋白及白细胞计数的影响[J].河北中医,2008,30(2)：126.
[17]吴圣贤,吴雪莲,黄政鑫,等.解毒软脉方抗动脉粥样硬化17例初步临床观察[J].福建中医药,2000,31(5)：8-10.
[18]丁书文,李晓.治疗冠心病的常法与变法[J].中医杂志,2004,45(6)：464-466.
[19]于月罡.针灸治疗冠心病心绞痛60例临床观察[J].中国中医药信息杂志,2008(4)：76-77.
[20]俞文全,许祥贵,吴焕淦.针灸治疗高脂血症的临床研究[J].上海针灸杂志,2011,30(3)：155-157.
[21]高社光,康日新,高莉,等.麝香通痹膏穴位贴敷治疗冠状动脉粥样硬化性心脏病心绞痛130例[J].河北中医,1999,21(3)：136.
[22]毛喜荣,李佩芳,王月兰.穴位注射治疗冠状动脉粥样硬化性心脏病102例的临床观察[J].针灸临床杂志,1995,11(2)：16-18.
[23]杨英,刘斌,毕力夫,等.降脂宁调血脂及抗脂质过氧化作用的实验研究[J]中华中医药杂志,2009,24 (5)：647-649.
[24]邱赛红,李福元,高雁.降脂消斑片对兔高脂血症合并动脉粥样硬化血脂的影响[J].湖南中医药大学学报,2009,29(3)：3.
[25]潘涛,顾勤.血脂清对实验性血脂异常大鼠的降脂及抗动脉粥样硬化作用[J].辽 宁中医杂志,2009,36(12)：2183-2185.
[26]焦宏,杜会博,陈彦静,等.桂枝汤对改善高脂血症心肌缺血大鼠微循环的作用[J].中国动脉硬化杂志,2011,19(12)：984-988.
[27]张斌霞,殷建峰,智瑜.血脉通2号颗粒对动脉粥样硬化鹌鹑血管内皮功能的影响[J].河南中医,2010,30(11)：1066-1067.
[28]季亢挺,唐疾飞,陈鹏,等.丹参素保护内皮祖细胞炎症损伤的机制研究[J].中国预防医学杂志,2010,11(8)：809-812.
[29]张旭静,王素春,范柳,等.当归、川芎、红花、人参萃取液对离体培养牛血管内皮细胞一氧化氮合酶的影响[J].解剖学杂志,2004,27(1)：36.
[30]陈咸川,杨宏杰,陈士明,等.单味当归抑制低密度脂蛋白氧化的方法研究和临床观察[J].上海中医药大学报,2001,15(4)：25.
[31]张军平,许颖智,李明,等.四妙勇安汤对动脉粥样硬化模型兔氧化应激及炎症反应的影响[J].中医杂志,2010,51(1)：72-74.
[32]赵学军,李任先,刘国普,等.理脾化痰方对食饵性动脉粥样硬化症家兔血管平滑肌细胞增殖和凋亡的调控[J].广州中医药大学学报,2001,18(2)：144-148.
[33]赵君玫,魏群,毕红征,等.淫羊藿甙对动脉粥样硬化家兔血管平滑肌细胞内质网应激的影响[J].中医学报,2010,25(4)：680-682.
[34]王宏伟,赵月华,熊一力,等.API0134对实验性动脉粥样硬化家兔血液凝固性和血栓弹力图的影响.中国动脉硬化杂志,1998,6(2)：109-111.
[35]胡发明,胡红丁.川芎嗪的实验研究及临床应用[J].中医研究,2004,17(3)：57-60.
[36]周宜轩,周磊,吴元杰,等.蓝黄胶囊对动脉粥样硬化家兔调节TXA2与PGI 2平衡的研究[J].中国中医急症,2005,14(4)：347.
[37]张俊峰,高振华,张桂英,等.黄芪、三七有效成分配伍抗动脉粥样硬化作用的实验研究[J].中西医结合心脑血管病杂志,2009,2(7)：2.
[38]王斌,管思明,李西栋.微米复方黄连制剂对高脂饮食喂养家兔核因子-κB及炎症因子表达的影响[J].中国中药杂志,2007, (6)：1207-1210.
[39]姜萍,李晓.中药调心饮对家兔动脉粥样硬化冠脉微血管密度及心肌NF-κB表达 的影响[J].中国微循环,2005, (4)：245-247.